









The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 




















       
 
Neuropsychiatric Profile of a Cohort of Perinatally 





 RENÉ NASSEN 
STUDENT NUMBER:  NSSREN001 
 
 
SUBMITTED TO THE UNIVERSITY OF CAPE TOWN 
In partial fulfilment of the requirements for the degree of 
Master of Philosophy in Child and Adolescent Psychiatry 
 Faculty of Health Sciences 
 




Prof John Joska  Department of Psychiatry and Mental Health,  
University of Cape Town 
 
Dr Catherine L. Ward  Department of Psychology, 
















I, ………………………………………, hereby declare that the work on which this 
dissertation/thesis is based is my original work (except where acknowledgements 
indicate otherwise) and that neither the whole work nor any part of it has been, is 
being, or is to be submitted for another degree in this or any other university. 
I empower the university to reproduce for the purpose of research either the whole 





















The Highly Active Antiretroviral Therapy (HAART) era in the mid-nineties signalled a 
dramatic change in the long-term outcome of Human Immunodeficiency Virus (HIV).  
Many children have shown significant neurologic benefit, and in particular, a decline 
in the incidence of HIV encephalopathy.  As increasing numbers of children have 
survived into adolescence and early adulthood new challenges have arisen, such as 
the detection and characterization of milder forms of HIV-associated neurocognitive 
deficits in children previously thought to be asymptomatic. 
 
In order to explore the neurocognitive and neuropsychiatric aspects of HIV in 
children initiated late onto HAART, a clinical case series is presented of nine 
children who underwent psychiatric evaluations, neurological examinations, and 
neurocognitive tests.  The children were referred to a neuropsychiatric clinic at an 
academic children‘s hospital in Cape Town, South Africa, between September 2004 
and August 2005.  In addition, data was collected from the medical records of the 
two infectious diseases clinics managing their HIV illness.  Following this, with a 
view to (a) comparing local findings with the published literature, and (b) to 
consolidate the reported neurocognitive and neuropsychiatric manifestations of 
children infected with HIV, a systematic review of the literature was performed.  
 
It was found that the majority of children were in the borderline to mild disability 
range of intellectual functioning. Neurological examinations revealed no 
abnormalities except for microcephaly in two children and brisk reflexes in one of the 
two.  Electroencephalograms (EEG‘s) were abnormal in two of the nine children.  
Magnetic Resonance Imaging (MRI) brain scans were normal in two referred cases.  
Four of the nine children were diagnosed with ADHD.  Other diagnoses included 
adjustment disorders (n=3), and oppositional defiant disorder (n=2).  The reviewed 
literature reports that Central Nervous System involvement and neurocognitive 
deficits are common and occur early in untreated, HIV positive children.  HAART 
has significantly reduced the incidence of severe forms of HIV-associated 
neurocognitive disorders, especially HIV encephalopathy, but mild to moderate 
problems persist.  Despite improvements in scores of broad based IQ tests, children 
continued to present with executive functioning deficits on neuropsychological 
testing, as well as significant learning problems.  Higher rates of psychiatric 













medications and hospital admissions, were evident compared to the normal (HIV 
negative) population. 
While a considerable reduction in disease progression and deaths has occurred in 
children treated with HAART, behavioural and scholastic difficulties continue to 
negatively impact on overall functioning and quality of life of children living with HIV. 
While early initiation of HAART is advocated, and may reduce the risk of severe 
forms of neurologic and neurocognitive disease, clinicians need to be able to assess 
and manage the minor neurocognitive and behavioural problems, as these can exert 
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This chapter describes the findings of research studies conducted prior to the Highly 
Active Antiretroviral Therapy (HAART) era exploring the neurocognitive, neurological 
and psychiatric presentations in treatment-naïve Human Immunodeficiency Virus 
(HIV) positive children or those on antiretroviral monotherapy. A brief description of 
antiretroviral agents, impact on progressive HIV encephalopathy (PHE) and 
potential neurotoxic side effects will be provided. 
 
During the mid-1990s the introduction of HAART, lately referred to as Combination 
Antiretroviral Treatment (CART), dramatically changed the nature of AIDS from a 
rapidly fatal disease to that of a chronic illness.  Combination therapies with 
Protease Inhibitors (PI) became the standard treatment regimen for children, 
adolescents and adults (Feingold AR et al 2000).  The impact of CART has 
significantly decreased the morbidity and mortality rates of HIV/AIDS.  Children are 
living longer and most are surviving into adolescence and some into adulthood 
(Thorne C et al 2002, Hazra R et al 2010).  Clinical and research issues pertinent to 
children have likewise shifted with their increased survival, to include concerns 
about the long-term neurocognitive sequelae of HIV and mental health issues 
(Mitchel CD 2006, Van Rie A et al 2007).  
 
The impact of HAART was experienced considerably later in South Africa, following 
the ‗roll-out‘ of the National Antiretroviral Programme in 2003, after years of 
pressure on the South African Government by the Treatment Action Campaign 
(TAC) and other activist groups (Achmat Z et al 2007). One effect of this has been 
that more people have access to antiretroviral medication, with the possibility of 
more children surviving to adolescence and adulthood (Eley B et al 2006, Davies 
MA et al 2009). While the release of the operational plan for the ‘Comprehensive 
HIV and AIDS Care, Management and Treatment for South Africa,’ in November 













that, by 2009, all HIV-infected individuals requiring ART would be able to access 
therapy within the public health care system (Department of Health).  However, the 
rollout has been criticized for its slow pace as funding, human, and infrastructural 
obstacles have impacted on the pace of the ART scale-up. Furthermore, the 
disparity in access to ART among the nine provinces persists: the more affluent 
provinces are receiving more donor funds (Ijumba P et al 2003, Meyers T et al 2007, 
Ojikutu B et al 2007).  Progress in the prevention of mother to child transmission 
(PMCTC) and ART rollout to children have been less than favourable, with 40% of 
total child deaths in South Africa still due to HIV.  South African Perinatally HIV 
infected children (PHIV) continue to be substantially denied the benefits of ART or 
only access treatment years after HIV diagnosis, and therefore remain at risk from 
HIV, both in terms of survival and poor long-term neurocognitive outcomes (Geddes 
R et al 2011).  
 
1.1.1 Impact of HIV on neurocognitive development in untreated HIV infected 
children 
 
A review of early studies examining the nature and impact of HIV on the 
neurocognitive development of PHIV children reveals that neurocognitive 
impairment occurs early, and progresses over time, in untreated perinatally HIV-
infected (PHIV) children, or children on mono-therapy (Aylward EH et al 1992, 
Mellins CA et al 1994, Chace C et al 1995, Gay CL et al 1995, Fundaro C et al 
1998). The pathophysiology of neurodevelopmental impairments may involve pro-
inflammatory dysfunction of microvascular processes that interplay with immune 
mechanisms at the synaptic level of the brain (Mekmulluka J et al 2009, 
Kapetanovic s et al 2010).  
    
The reported prevalence rates of neurocognitive impairment ranges from 8-60% in 
PHIV children.  Generally, neurocognitive performance is poorer in HIV positive 
children than Perinatally Exposed Uninfected Children (PHEU) and HIV negative 
HIV Unexposed (HNU) children.  In the infected group, intellectual function ranges 
from above average to intellectually disabled.  Neurocognitive scores, however, tend 
to cluster in the low average to borderline range of intellectual functioning (Levenson 
J et al Mellins CA 1992). 
 
Studies where cohorts underwent neuropsychological testing revealed that 













in HIV positive children. These problems were identified in children where 
neurocognitive deficits were not identified on broad IQ tests.  Testing identified 
deficits in mental processing, sequential processing, comprehension, memory, 
visuospatial, and time orientation tasks (Tardieu M et al 1995). Other studies 
revealed deficits suggestive of frontal lobe dysfunction, such as in sustained 
attention, processing speed, motor speed and visuomotor integration (Fundaro C et 
al 1998, Fishkin PE et al 2000).  Deficits in fine motor performance were related to 
CD4 count, suggesting that this could be used as a behavioural marker of immune 
system compromise (Blanchette N et al 2002, Foster C et al 2006).  
 
A few studies attempted to identify whether HIV is an independent risk factor for 
neurocognitive deficits (Chase C et al 2000, Mc Grath N et al 2006).  The results 
were equivocal, with some studies supporting the hypothesis that HIV had an 
independent and substantial impact on the neurocognitive performance of HIV-
infected children (Chase C et al 2000, Blanchette N et al 2001). The negative 
studies however suggested that risk factors other than HIV may be the main ‗drivers‘ 
of developmental deficits observed, including exposure to illicit drugs pre-natally, 
poverty and poor nutrition. A number of studies did reveal that poor neurocognitive 
performance was associated with more severe disease, higher baseline viral loads 
and more severe immune compromise (Nozyce M et al 1994, Pollack H et al 1996, 
Pearson DA et al 2000). These studies found that the more severe the immune 
compromise, the more severe the neurocognitive deficits, regardless of HIV status.  
The conclusion reached was that immunosuppression is a unique predictor of 
overall neurocognitive functioning, in infected or uninfected children (Henry R et al 
1996, Brouwers P et al 1995). 
 
There appears to be an association between the degree of developmental delay and 
the timing of HIV infection.  Children, who test HIV positive at birth, have a 14.9 
times increased rate of developmental delay during the first three years of life 
compared to those who tested positive at a later age.  Studies also suggest that 
early infection is not only associated with a worse neurocognitive outcome, but also 















Studies that explored the impact of environmental factors on neurocognitive 
outcomes in HIV infected children were the most challenging and failed to 
definitively establish the independent neurocognitive effects of HIV compared to low 
socio-economic status, intrauterine exposure to illicit drugs, and other adverse 
environmental risk factors (Boivin MJ et al 1995, Kullgren K et al 2004).  However, a 
few studies demonstrated that the cumulative impact of adverse environmental 
stressors in addition to HIV positive status conferred a worse neurocognitive 
outcome (Mellins CA et al 1994).  A few studies identified protective factors against 
the adverse neurocognitive impact of poverty, irrespective of HIV status.  These 
factors were the quality of the caregiver-child interactions, the caregiver-child ratio, 
parenting skills and provision of stimulation such as toys and reading material 
(Coscia JM et al 2001, Kullgren KA et al 2004).  
 
1.1.2 Studies conducted on the African continent (other than in South Africa) 
 
Six studies were conducted in Rwanda, The Democratic Republic of Congo (DRC), 
Uganda and Tanzania between 1993 and 2006 (Msellati P et al 1993, Boivin MJ et 
al 1995, Boivin MJ et al 1995, Drotar D et al 1997, Bagenda D et al 2006, Peterson 
NJ et al 2001, Mc Grath N et al 2006).  These studies are important as the samples 
were naïve to Antiretroviral Treatment (ART) and born to mothers who did not abuse 
drugs. In contrast, most studies in the developed world were conducted in urban, 
poverty stricken settings, with children born to drug abusing mothers. Likewise, a 
study conducted in South Africa (Smith L et al 2008) was conducted in a peri-urban 
setting where the likelihood of prenatal exposure to illicit drugs was high.  That study 
was therefore excluded from this analysis. Prior to the HAART era, it was rare to find 
cohorts that were entirely ART naïve as they were often treated with one or two 
drugs. The African studies therefore, may have more clearly identified the negative 
neurocognitive factors related to the virus, rather than those related to 
environmental factors such as perinatal exposure to drugs or treatment effects.  The 
results of the six studies conducted in Africa were surprisingly similar, in that PHIV 
children continued to perform more poorly than PHEU and HIV negative unexposed 
(HNU) children do.  Older children, however, demonstrated similar performance to 
PHEU children and HNU controls suggesting that these treatment naïve children 
may have represented a group of  ‗survivors‘ infected by a less virulent strain of HIV.  
This unique group of slow performers present later by progressing to an AIDS 
diagnosis.  This is related to transmission of low fitness viruses by the mother as 













immune recipient (infant).  This facilitates immune control and reduces replicative 
capacity (Ferrand R et al 2009, Thobakgale C et al 2009, Prado J et al 2009).  
Neuropsychological testing in this group of African children likewise produced a 
similar profile to those studies conducted in the USA, with language, spatial and 
memory deficits evident. These studies, therefore, may confirm an independent 
negative neurocognitive effect of HIV. However, the low number of studies and small 
sample sizes remain mitigating factors in definitively establishing an independent 
adverse neurocognitive effect of HIV. 
 
1.1.3 Neurological manifestations of HIV in children and adolescents 
 
Prior to the advent of HAART, PHIV children presented at an early age and 
commonly with progressive neurological disease, compared to adults.  Early 
estimates were that 80-90% of PHIV children would develop Central Nervous 
System (CNS) and neurocognitive dysfunction (Ultmann M et al 1987, Belman A et 
al 1988, Habibi P et al 1989, Diamond GW et al 1989, Tardieu M et al 1994, Belman 
A et al 1994). HIV therefore invades the developing CNS earlier and with greater 
severity than observed in adults, with a more rapid progression to death (Schwartz L 
et al 2006).  HIV causes neuronal damage in the brain by being both directly 
neurotoxic and causing an indirect neuro-inflammatory response.  It crosses the 
Blood-Brain Barrier (BBB) via a ‗Trojan-horse-type‘ mechanism, by infecting 
macrophages.  Once in the brain, it invades and activates microglial cells, and 
produces neurotoxins that lead to inflammatory processes, neuronal damage, and 
cell death.  It is thought that the severity of these clinical and neurological deficits is 
linked to the extent of this damage (Dube B et al 2005, Crawford JR et al 2010).  
The presence of neurological complications, particularly abnormalities on imaging 
are associated with poorer neurocognitive outcomes and poorer overall prognosis 
compared to neurologically asymptomatic children.  
 
Common reported neurological sequelae of HIV in children are microcephaly, 
encephalopathy, myelopathy and peripheral neuropathy.  Primary lymphoma of the 
CNS and metastasis of systemic lymphoma are common types of CNS tumours in 
HIV infected children (Kieck J et al 2004).  Cerebrovascular Accidents (CVA‘s) 
appear either as a result of HIV or secondary to AIDS associated illness, for 
example, cardiomyopathy, thrombosis or embolism. The most severe neurological 
manifestation of HIV in children is progressive HIV encephalopathy (PHE) which 













(Wilmshurst J et al 2006, Chiriboga CA et al 2005).  Psychomotor slowing and 
apathy are early manifestations of neurocognitive impairment and early dementia in 
infected children. In young children, there can be a loss of, or a failure to acquire, 
new developmental milestones, and, in older children, a deterioration in school 
performance.  Psychometric tests often show a decline in composite IQ scores.  
Speech and language difficulties present with predominantly expressive but also 
receptive language difficulties. Some children develop microcephaly because of 
both cortical and sub cortical atrophy. Memory impairment may be a manifestation 
of HIV related central nervous system disease, with deficits in visuospatial memory, 
verbal learning and rote recall. Disturbances of motor functioning are the most 
frequent neurological manifestation and presents initially with changes in gait and 
toe-walking, because of hyperreflexia and increased tone. Other early presentations 
are gross and fine motor deficits with clumsiness, low muscle tone, and poor pencil 
grip.  With further deterioration, there is a progression to spastic paresis, rigidity or 
muscle weakness, dystonic posturing, ataxia, tremor, and seizures (Tardieu M et al 
1999).  The third manifestation of the encephalopathy triad is behavioural 
aberration, with typical symptoms being apathy, uncooperativeness, and 
aggression.    Disturbances of affect (emotional lability) and problems with 
hyperactivity and inattentiveness have also been noted. In the absence of significant 
social stressors, behavioural problems tend to escalate as the disease becomes 
more advanced (Wachsler-Felder JL et al 2008).  
 
The neuropathological finding most commonly associated with developmental and 
motor deficits is myelinopathy.  Myelination of the frontal and parietal regions 
continues through adolescence to early adulthood.  Deficits in higher cortical 
functioning such as language, sequencing and sensory integration may, therefore, 
be expected in infected children.  Advanced developmental skills, such as, visual 
motor- integration, processing speed, sequential processing and verbal memory 
only develop in later childhood, so will not be detected early or with broad based 
neurocognitive tests. 
 
Two relatively distinct clinical courses have been identified, the more devastating 
and severe rapidly progressive encephalopathy of childhood, and the more benign 
slowly progressive course.  Age of onset of the rapid PHE is usually under one year 
and appears to be related to the occurrence of pathological events during the late 













2000).  Slowly progressive encephalopathy is a much less severe neurological 
syndrome and commonly presents with hypotonia, marked delays in motor 
milestones, neurocognitive delay, and language delay (both expressive and 
receptive) (Ojukwu IC et al 2007).  Radiological examination (CT and MRI) usually 
reveals cortical atrophy and ventricular dilatation.  Calcifications of the basal ganglia 
and white matter subcortical changes have been found to be consistent features.  
There appears to be a direct correlation between progression and severity of 
encephalopathy and Computer Tomography (CT) scan findings.  Cerebrospinal fluid 
(CSF) viral loads are higher in patients who present with neuropsychological 
impairments.  In most instances, viral titres decrease after initiation of HAART, but in 
some patients they remain high (Mitchell CD 2006, Tardieu M et al 1999, Van Rie A 
et al 2007). 
 
1.1.4 Neuropsychiatric presentations in HIV infected children and adolescents 
 
Pre-HAART studies, reviews and reports specifically exploring the psychiatric 
manifestations of HIV in children and adolescents are limited and suggest that 
Attention Deficit Hyperactivity Disorder (ADHD), depression and anxiety disorders 
are common (Havens JF et al 1994, Tardieu M et al 1995, Moss H et al 1998, Lwin 
R et al 2001).  Studies specifically exploring psychiatric disorders in HIV positive 
adolescents revealed very high lifetime prevalence of psychiatric disorders, 
particularly depression, substance abuse and conduct disturbances (Brown LK et al 
2001, Pao M et al 2000, Williams PL et al 2010).  Higher rates of psychiatric 
hospitalisation and psychotropic drug use were evident in this psychiatrically ‗at-risk‘ 
population (Gaughan DM et al 2004, Wiener L et al 2006, Donenberg GR et al 
2005).  Recent reviews by Sharko and Roa described a limited literature with small 
samples, inconsistent measurements, and wide age ranges.  A review of existing 
research by Sharko et al yielded eight studies, between 1993 and 2004.  However, 
participants were not all perinatally infected and it was unclear whether participants 
in later studies were on ART regimens.  Outcomes concurred with other studies, 
with higher rates of ADHD, depression, and anxiety disorders (including PTSD) 
being reported (Sharko et al 2006).  The review by Rao similarly revealed few 
studies on psychiatric disorders, with low rates of psychosis and mania in children 
and adolescents compared to HIV positive adults (Rao et al 2007).  Studies were 
not able to ascribe those aetiological factors related to the virus and those due to 













2006).  However, some studies demonstrated an equal male: female ratio in the 
incidence of ADHD (Nozyce M et al 2006).  This is in contrast to the common 
gender distribution of ADHD, which has a male preponderance among HIV negative 
children (Pliszka S et al 2007).  This discrepancy may suggest a partial viral 
aetiology in the presentation of ADHD in HIV positive children.  Another finding 
suggestive of a possible viral aetiology is that the presence of depressive symptoms 
appeared to be associated with disease progression and a poorer prognosis 
(Misdrahi D et al 2004). 
 
1.1.5 Antiretroviral medication in children and adolescents 
 
There are five main classes of antiretroviral drugs: Nucleotide Reverse 
Transcriptase Inhibitors (NRTIs), Non Nucleotide Reverse Transcriptase Inhibitors 
(NNRTIs), Protease Inhibitors (PIs), and Fusion Inhibitors (FIs).  Newer classes of 
drugs are Entry Inhibitor CCR5 co-receptor antagonists, and HIV Integrase Strand 
Transfer Inhibitors (INSTIs) (Penazzato M et al 2010, Cysique LA et al 2009).  There 
are two main mechanisms of action of ART, namely inhibition of viral replication 
(NRTIs, NNRTIs and PI‘s) and inhibition of viral entry into the target cell (FIs) 
(Bartlett J et al 2004).  FIs are administered via subcutaneous injection that makes it 
a less favourable option for use in children.  Long-term use of the antiretroviral 
agents has raised a number of concerns, particularly in relation to the 
neurocognitive impact of these drugs.  Problematic issues are the penetrance of the 
Blood Brain Barrier (BBB), neurotoxic and psychiatric side effects, and drug–drug 
interactions between antiretroviral and psychotropic medications. 
 
Antiretroviral medications are not equal in their ability to penetrate the BBB.  The 
issue of brain penetrance is an important one with regards to effective management 
of neuropsychiatric manifestations.  Lack of brain penetrance means that despite 
systemic improvements and decreased viral loads, the brain potentially can remain 
a sanctuary site for the virus, resulting in compartmentalisation.  This would ensure 
viral persistence (and in some cases, genotypic divergence) and continued viral 
replication in the CNS, higher Cerebrospinal Fluid (CSF) viral loads and a potential 
source of therapy resistant strains (Patel K et al 2009).  The NRTIs AZT, Stavudine 
(d4T), Lamivudine (3TC) and Abacavir (ABC) and the NNRTI, Nevirapine (NVP), 
penetrate the BBB effectively.  Efavirenz, however, is highly protein bound and 













CSF (Chen L et al 2007, Patel K et al 2009).  In spite of this, it has still been shown 
to achieve a sufficient concentration to inhibit replication of HIV.  The Protease 
Inhibitors, with the exception of Indinavir have relatively poor BBB penetration, 
which has generated concern that PI based HAART, would not effectively treat CNS 
disease.  Studies have shown, however, that PIs effectively reduce CSF viral loads 
to undetectable levels.  MRI scans have also shown reversal of white matter lesions 
and metabolic improvements on Proton Magnetic Resonance Spectroscopy (Garvey 
L et al 2011).  A number of cross-sectional and longitudinal studies have 
documented benefits for the full range of HIV associated neurocognitive symptoms 
with particular improvements in neurocognitive speed in children on PI-based 
HAART regimens (Raskino C et al 1999, Letendre S et al 2008, Sanchez-Ramon S 
et al 2003).   
 
Agents used to treat HIV infection have been identified as a potential cause of 
neurological and psychological side effects.  ART that penetrates the CNS may in 
some cases cause delirium, psychiatric presentations, neurocognitive impairment 
and seizures.  For example, Efavirenz and AZT both have good CNS penetration, 
but are themselves associated with potentially significant neuropsychiatric 
complications.  The CNS side effects of Efavirenz such as dizziness, vivid dreams, 
headaches, confusion and perceptual disturbances have been reported in adult 
studies. A case study by Louwenhaupt reported psychosis in a twelve year old girl, 
with an increased serum level of Efavirenz (Lowenhaupt EA et al 2007), and another 
study by Cicarelli et al reported neurocognitive disorders associated with Efavirenz 
use in a group of otherwise asymptomatic HIV positive adults, suggesting potential 
neurotoxicity of this drug (Ciccarelli N et al 2011).  Side effects sometimes 
associated with AZT therapy are confusion, agitation, insomnia, mania, depression, 
myalgia, and headache (Bhana N et al 2002). Reports of potential neurotoxic side 
effects of ART are from adult studies, with no longitudinal prospective follow up 
studies exploring long-term adverse CNS effects of ART in the paediatric population 
Langford TD et al 2002, Barlett J et al 2004, Nath A et al 1998).   
 
The potential for drug-drug interactions between psychotropic and antiretroviral 
medications is related to the cytochrome P450 enzymes of the liver, which 
metabolises antidepressants such as the Selective Serotonin Reuptake Inhibitors 
(SSRIs) and atypical neuroleptic agents.  They include P450, 2D6, 1A2, 2C18 and 













especially the PIs.  There is, thus, a potential for competition by these medications 
resulting in raised or toxic levels of either or all classes of drugs (Gonzalez A et al 
1998, Chen LF et al 2007). A further complication is that a number of SSRIs and PIs 
potently inhibit these enzymes (Thompson A et al 2006).  
 
Other adverse reactions associated with ART may indirectly affect the 
neurodevelopmental status of infected children such as adherence, tolerability, drug 
resistance and Immune Reconstitution Inflammatory Syndrome (IRIS), which may 
manifest as a neurological complication, so called ‗neuroIRIS‘ (Smith K et al 2009).  
Rigorous adherence to complex medication regimes is important, as inconsistent 
use leads to the development of viral resistance (Sethi AK et al 2003). Children are 
dependent on adults (parents and teachers) to receive their medication.  Therefore, 
an evaluation of caregivers, the home and the educational environment is an 
essential aspect of the management of children on antiretroviral medication.  
Adherence may be negatively impacted upon by the child‘s level of neurocognitive 
functioning (older children who self- administer medication), stigma, shame and 
secrecy (Brown LK et al 2000). 
 
Clinical response to ART may differ in children compared to adults as they tend to 
have higher baseline HIV Ribonucleic Acid (HIV RNA) levels, which places them at 
higher risk of treatment failure or poor response to treatment.  Viral loads also tend 
to decrease more slowly after initiation of treatment.  In some children, an 
aggressive therapeutic approach, using multiple drug regimens (4 or 5 drugs), at 
high doses, is necessary to ensure treatment success (‗mega HAART‘).  This 
strategy, though possibly virologically successful, increases the risk of increased 
toxicity and the use of large quantities of tablets (King JR et al 2003). 
 
Finally, studies have demonstrated that the pharmacokinetics of ART can vary 
dramatically by age in the paediatric population.  The cytochrome P450 system 
(which metabolises the PIs) is not fully developed in children.  Drug distribution, 
metabolism and clearance may also be very different to adults, which may impact on 
paediatric dosages prescribed and responses to treatment. Decreased metabolism 
increases the risk of elevated plasma concentrations of the drug and increases the 
risk of drug toxicity.  There are few studies, which evaluate the pharmacokinetics of 
these drugs in the paediatric populations.  This may impact negatively on decisions 














1.1.6 Access to ART and the implications for long-term neuropsychiatric outcomes 
 
The decline in HIV encephalopathy has been one of the most dramatic effects of 
HAART, with reductions in prevalence in PHIV children from 35-50%, to less than 
2% (Roberson KR et al 2007, Chiriboga CA et al 2005, Hazra R et al 2007).  During 
the pre-HAART era it was the most devastating manifestation of HIV in children, 
resulting in severe global neurocognitive deficits. However, as children survive into 
adolescence subtler neurocognitive deficits may be evident, despite long-term 
treatment with HAART.  These may have a significantly negative impact on youth as 
they survive into adulthood. 
 
Causes of the persistence of the milder forms of HIV Associated Neurocognitive 
Deficits (HAND) in the HAART era are multiple.  Possible explanations include late 
initiation of ART (with irreversible brain injury prior to initiating treatment), incomplete 
viral suppression in the CNS due to poor CNS penetration of certain drugs and the 
presence of drug-resistant viral strains.  Another possibility suggested is that 
prolonged exposure to inflammatory responses and neurotoxic viral proteins could 
result in neural injury or dysfunction (Cysique L et al 2009, Joska JA et al 2010, 
Heaton RK et al 2011).  Neurobehavioral disorders have been reported since the 
pre HAART era, with improvements demonstrated after initiation of mono- or dual 
therapy.  However, children on HAART have shown minimal further improvements, 
with recent studies demonstrating high rates of psychiatric disorders in PHIV youth 
as they enter adolescence. 
 
Early initiation of ART, before the age of 6 months, is associated with decreased 
mortality and superior clinical outcomes (Purchase SE et al 2011, Violari A et al 
2008).  A study by Faye et al revealed that in infants initiated on treatment before 
age six months, none presented with encephalopathy or opportunistic infections by 
age two.  However, 6 out of 40 infants initiated on ART after 6 months presented 
with 7 AIDS defining events, 3 of which were encephalopathy (Faye A et al 2004). A 
study conducted in South Africa, the CHER study (Children with HIV Early 
Antiretroviral Treatment), demonstrated a 76% reduction in infant mortality among 
infants initiated on ART before age 12 weeks (Violari A et al 2008).  Furthermore, 
superior neurodevelopmental scores were achieved at 11 months, compared to 













of this strong evidence, initiation of HAART is recommended in the first year of life in 
the developed world and resource limited settings (Horwood C et al 2009, Jaspan H 
et al 2011). 
 
Within the context of what has been elaborated in this chapter, it is important to 
define the neuropsychiatric profile of South African HIV positive children.  Most 
school age children have not benefitted from early initiation of ART and may 
therefore present with significant residual neurocognitive and behavioural problems 
because of late initiation of treatment.  The following chapter describes a clinical 
cohort of nine South African children referred to a neuropsychiatric clinic one year 
after initiation of HAART and who presented with behavioural problems and 















This chapter describes the findings of a clinical case series of a cohort of perinatally 
HIV infected children, referred to a neuropsychiatric clinic, at a children‘s hospital. 
 
2.1 MOTIVATION FOR THE STUDY  
 
The Division of Child and Adolescent Psychiatry of the Red Cross Children‘s 
Hospital has provided a consulting service to a religiously affiliated children‘s home, 
which accommodates HIV positive children.  The children‘s home is situated in the 
city of Cape Town.  It accommodates children from infancy to the age of thirteen 
years.  Some children have been accommodated till the age of eighteen because of 
placement difficulties.  It is one of the few children‘s homes that have 
accommodated HIV positive children.  Over the years they have striven to provide 
the necessary care for chronically ill and dying children.  The children are raised in 
the Catholic faith and cared for by an order of nuns and childcare workers.  The 
children live in a relatively protected environment and appear to be shielded from 
the (often severe) psychosocial stressors experienced by infected children living in 
the community. 
 
Clinicians from the Child and Adolescent Psychiatry service undertook monthly 
consultations to staff.  Assessments of children with emotional and behavioural 
problems were undertaken.  Common problem behaviours were discussed at these 
consultations.  The children were referred to the hospital when they experienced 
peer group difficulties, aggression, and hyperactivity.  Other issues like coping with 
illness, frequent hospitalizations, and deaths were explored with both the staff and 
the children.  It was noticed that as the children approached adolescence (ten to 
twelve years old), they tended to become concerned about physical appearance (as 
they were usually smaller in stature than their peers), the impact of the disclosure of 
their HIV status, and leaving the institution when they turned thirteen years old.  A 
number of the children had to cope with the emotionally fraught experience of being 
reunited and placed with estranged biological parents and families on reaching the 














A substantial number of the children placed at the particular children‘s home 
benefited from an externally funded ARV programme.  This was spearheaded by a 
paediatrician at a local general hospital (Groote Schuur), prior to the rollout of the 
national ARV programme in late 2003 and early 2004.  There was a dramatic 
improvement in the physical health of the children with a significant reduction in the 
number of deaths on receiving ART.  Overall academic performance, however, did 
not improve and either remained the same or deteriorated to the extent that some of 
the children were removed from mainstream schools and placed in special schools 
termed ELSEN schools.  ELSEN is an acronym for ―Education for Learners with 
Special Education Needs‖.  These are schools which provide a full package of 
remedial services, by a multidisciplinary team, to learners with learning difficulties or 
who may experience other barriers to learning.  Problem behaviours also appeared 
to escalate within the first year after ART was started.  Since the middle of 2004, 
there were requests to assess a group of children who were presenting with the 
following pattern of behaviour: disturbed and at times bizarre behaviour (episodes of 
aggression, perceptual disturbances and confusion), as well as a neurocognitive 
decline, with the impression of a deterioration of academic ability (in reading and 
writing), and in social skills.  This raised a concern about the cause of this 
presentation, as it was unclear whether it was due to psychosocial stressors, side 
effects of the ART, or because of a poor response to the ARV medications.  
 
There is a substantial literature describing the impact of institutional rearing on 
children.  Earlier studies consistently report more negative outcomes socially, 
academically and emotionally for children raised in institutions and more favourable 
outcomes for children placed in foster care.  Outcomes are reported to be even 
more favourable when children are placed in the care of biologically related families 
(Rutter M 2000, Zeanah CH et al 2000, Smyke AT et al 2007, Van Ijzendoorn MH et 
al 2008).  Institutionalized children are exposed to multiple carers, as opposed to 
one or two parents in foster homes.  They often display indiscriminate attachments, 
and poor interpersonal boundaries (Smyke AT et al 2002).  Furthermore, there is an 
increased risk of abuse, peer relational problems and psychiatric disorders, 
particularly Attention Deficit Hyperactivity Disorder (ADHD), depression and 
substance abuse (Roy P et al 2004).  Loss of contact with biological families tends 
to confer a worse outcome.  More successful family reconstitution is associated with 













opposite, with more negative outcomes (delinquency, risk behaviours, suspensions 
and externalizing behaviours) in youth reunified with biological families (Taussig H et 
al 2001).   
 
Recent reviews and selective meta-analyses on residential care in developed 
countries suggest that outcomes may be more favourable than previously assumed.  
Positive outcomes are demonstrated where behavioural and therapeutic methods 
focusing on family involvement are employed (Knorth E et al 2008).  It is not clear 
whether one can generalize these outcomes to institutionalized HIV positive children 
or AIDS orphans living in developing countries.   
 
Such environments are compromised by a lack of economic resources, therapeutic 
and supportive services, which may severely compromise biological families‘ 
capacity to provide adequate care for orphaned relatives (Richter L et al 2004, 
Madhavan S et al 2004).  Studies conducted in Africa, focused on AIDS orphans, 
suggest that institutionalized care in adverse environments may provide a degree of 
stability and quality of care which is arguably superior to community based care 
(Kimani C et al 2009, Beard J et al 2005).  Recent studies such as ‗The Positive 
Outcomes for Orphans Study‘, conducted a survey in six sites across five ‗less 
wealthy‘ countries and reported that physical growth, cognitive and emotional 
functioning were no worse for institution-reared than community based children.  
The hypothesis that institutional care is systematically associated with poorer 
outcomes was therefore not supported by this study (Whettan et al 2009).         
 
As the treating clinician and visiting consultant to the children‘s home, it became 
evident to me that the children were possibly experiencing a number of stressors, 
which could explain their clinical presentations.  The motivation for this study was 
therefore provided by the need to clearly identify the multiple factors (biological, 
















2.2 PURPOSE OF THE STUDY 
 
The purpose of the study is to describe the medical and neuropsychiatric 
presentations of a sample of PHIV children who have been treated with antiretroviral 
medications for more than one year. 
 
2.3 THE SPECIFIC OBJECTIVES OF THIS STUDY 
 
The specific objectives are to identify, with reference to the literature on paediatric 
HIV and ART, possible reasons for the clinical presentations in the sample of 
children.  This will be done in order to inform the hypotheses for a larger study by 
describing the factors related to the human immunodeficiency virus, those related to 
treatments administered and those related to the broader psychosocial factors 




 2.4.1 Study Design 
 
This descriptive study consists of the clinical cases manifest by the first HIV positive 
children referred to a newly established neuropsychiatric clinic at the Red Cross 
Children‘s Hospital and who underwent assessment and follow up.  Case files and 
medical records were evaluated and analysed.  Medical records of the same 
children were also examined at another treating hospital involved with the children‘s 
care (Groote Schuur Hospital).  Inclusion criteria were children thirteen years and 
younger, with a documented history of vertical/perinatal HIV infection, who had been 
initiated on ART for at least one year at the point of first evaluation at the clinic.  The 
children were a sample of institutionalised children, referred to the neuropsychiatric 
clinic with behavioural problems, over a course of one year (Mid 2004-mid 2005).  
Other children referred during that period were living in the community in the care of 
family.  Children resident in the community were likely to have experienced different 
home circumstances and psychosocial stressors compared to institutionalized 













to control for various confounding factors the following children were therefore 
excluded from the sample: non-institutionalized children, age fourteen years and 
above, transfusion-infected children, those who were not vertically/perinatally 
infected (history of sexual molestation, or where the history was unclear) and 
children not initiated on ART.  Clinical notes were reviewed and collated at various 
points over a one-year period.  
 
 2.4.2 Study population and sampling 
 
The study sample consisted of nine perinatally infected, institutionalized children 
aged from five to thirteen years and six months referred to a neuropsychiatric clinic 
at the Red Cross Children‘s Hospital between September 2004 and August 2005.  
All the children had been on ART for more than one year.  The children were 
referred for a neuropsychiatric assessment, as there were concerns about 
behavioural difficulties, new onset of psychiatric symptomatology and deteriorating 
academic performance and behaviour despite initiation of ART.  There were four 
girls and five boys in the sample.  The age range at the time of referral was five to 
thirteen years old.  Seven of the nine children were ten years and older.  Other 
clinicians within the child and adolescent mental health service, having been 
previously assessed and managed for behavioural and emotional problems, 
previously evaluated three of the children.  The three children were therefore 
internally referred to the neuropsychiatric clinic, because of a further deterioration in 
behaviour, appearance of new symptoms and to exclude an organic cause for the 
clinical presentation.  All, but one, of the children attended school regularly.  This 
child was registered at a mainstream school, but had not attended during that year 
due to ill health.  All the children were on ART for more than one year and had been 
adherent to treatment regimens.  Three children were on a second regimen of ART, 
because of adverse side effects to prior treatment.   
 
 2.4.3 Measurements 
 
The children were psychiatrically evaluated by a child and adolescent psychiatrist, 
(myself) and then referred to a paediatric neurologist for neurological examination.  
Children were referred to a clinical psychologist for neurocognitive testing.  
Psychometric assessments were deemed valuable in order to establish the cognitive 













functioning had deteriorated or remained stable, in those previously tested.  Patient 
demographics, such as the name, age, gender, address, contact telephone number, 
and hospital folder number, were obtained from the hospital folders.  Clinical case 
notes of all clinic visits including the visits to the infectious diseases and the 
neuropsychiatric clinics were reviewed.  The case notes provided information about 
compliance with visits and medical treatment, the child‘s current physical health 
status (including a history of recent hospitalizations), and their current clinical HIV 
staging.  The records also provided information about the current ART regime and a 
list of other medications that were prescribed for the child.  Results of CD4 counts 
and viral loads provided information about the current staging of the disease and the 
response to treatment (for example, a rise in CD4 count since initiation of ART).  
Other tests such as liver function, renal function, and full blood count (FBC) provided 
additional information about the child‘s health status and gave clues about possible 
toxic side effects to the medication.  Information documenting the children‘s health 
status (particularly relating to HIV disease) was important as their medical status, 
disease stage and treatments received would have some impact on the psychiatric 
presentation and management plan, as well as overall prognosis and outcome. 
 
The outcome of the neurological evaluation and results of neuroimaging tests, such 
as CT and MRI scans, were examined in order to obtain information about the 
patients‘ neurological status.  Results of Electroencephalogram (EEG) tests 
conducted on all the children were documented.  The results of psychometric tests 
administered were recorded.  Tests administered were the Junior South African 
Individual Scale (JSAIS), that was used to test children under eight years old and 
the Senior South African Individual Scale Revised (SSAIS-R) for the older children.  
Information obtained from the medical records was summarized and together with 
summaries of the case notes of the psychiatric, neurological and neurocognitive 
evaluation, formed the basis of the clinical case series.  
 
 2.4.4 Ethical and legal considerations 
 
A number of ethical and legal issues have been taken into consideration.  Informed 
consent was obtained from the legal guardians, to present the clinical material as a 
case series for a research study.  Consent was obtained to access and summarize 













Hospital.  Clear information was provided with regard to the goals of the study and 
the guardian was informed of potential risks, as well as benefits of participating in 
the study.  Where possible (depending on the child‘s neurocognitive ability), the 
child was informed about the study and assent was obtained.  Access to the medical 
records was limited to the clinicians involved in the clinical assessment.  Children 
participating in the study were not mentioned by name and data was kept in a safe 
and secure environment.  The investigator was the only person able to link clinical 
data to the child‘s name.  Psychometric assessments were not conducted at the 
hospital.  Children were tested in a pleasant ‗child-friendly‘ environment. 
 
The study is deemed to benefit the participants in a number of ways; for example, 
the routine psychometric assessments have informed whether the children are 
placed in the correct academic environment.  As such it has assisted in making 
decisions about transfer from a mainstream school to an ELSEN school or training 
centre.  The benefit of psychiatric and neurological evaluation is to contribute to the 
knowledge of the psychiatric course of HIV in children on ART.  There was also 
regular liaison with the treating clinicians at the Infectious Diseases Clinics.  
Because of this contact, problems with the children‘s health requiring their attention 
were timeously discussed.  No costs were incurred for the clinic visits, investigations 
and psychometric assessments, as committed children (Act 74) are treated free of 
charge under the current state hospital fees structure.  Consent to conduct the study 





The following is a brief description of the children evaluated.  Before the cases are 
discussed I will describe the procedure followed.  I, a Child and Adolescent 
Psychiatrist, conducted the initial psychiatric evaluations and follow up visits.  A 
history for each child was compiled by interviewing the child, the caregiver, and the 
Social Worker from the children‘s home.  Collateral information was gathered from 
the teacher and treating clinician at the Infectious Diseases Unit (Groote Schuur 
Hospital).  The initial clinical interview was conducted with the child and the 
caregiver.  Psychiatric diagnoses were obtained via unstructured clinical interviews 













Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM IV) 
classification system was used to evaluate the presence of psychiatric disorders.  
The children were all referred to the neurologist on the team, who conducted a 
neurological examination and referred for neuroimaging, when indicated.  All 
children were referred for EEG testing.  A clinical psychologist on the team 
conducted Neurocognitive testing.  The children were subsequently followed up by 
myself, at the clinic and, in addition, referred within the child psychiatry service for 
further therapeutic interventions.  I conducted monthly meetings at the children‘s 
home, where I met with the caregivers and the social worker based at the children‘s 
home. 
 
Case 1 (5 years, 1 month) 
 
Case 1 was admitted as an infant after his mother died, with no further contact with 
his biological family.  Date and age of HIV diagnosis was not recorded.  He was 
initiated on ART at the age of three years, as part of a research study.  CD4 counts 
pre and post treatment were 699 and 821.  The treatment regime was AZT, 3TC, 
and NVP.  There were five hospitalizations prior to initiation of ART, for 
gastroenteritis, pneumonia, and a severe skin rash. 
 
He was five years old at the time of the referral to the neuropsychiatric clinic and 
was one of twelve children living in a house on the premises of the children‘s home.  
Eight of the children had been placed in the community over a short period (within 
less than two months, most were alternately placed) as a decision had been made 
to establish a hospice for adults on the premises.  During this time, he became 
withdrawn, mute, sucked his thumb, and insisted on being fed baby food.  He 
displayed disorganized behaviour in that he pulled down the curtains, cut his 
clothes, and became fearful and restless at night.  He would settle when pacified 
and taken into the room of his caregiver for the night.  During a home visit, it was 
evident that he was reacting with anxiety to the departure of the children and the fact 
that the house was clearly being vacated.  One of the caregivers was clearly 
distressed and struggled herself to come to terms with the speed with which the 
children were being placed.  However, some staff members appeared to be 
emotionally disconnected from the children and did not appear to empathize or 
recognize that the situation could be emotionally distressing to them.  They 













children, rather than fulfilling a parental role.  School reported a quiet, inhibited child 
who was inattentive and hyperactive. 
 
Mental state examination revealed an inhibited, anxious child who struggled to play 
or express himself.  Neurological examination and EEG were normal.  
Neurocognitive testing (done when he had settled) revealed an intelligence quotient 
(IQ) in the average range.  Intervention consisted of alternative placement in a 
smaller environment and with caregivers that are more regular.  He was placed in 
one of the community cottages (along with six other boys) and attached positively to 
one of the caregivers, after which most of the anxiety symptoms dissipated and he 
settled rapidly.  However, the ADHD symptoms persisted and a trial of 
Methylphenidate was initiated, with good response, at low dosages (he was of low 
weight, so dosage not increased). 
 
Case 2 (7 years, 1 month) 
 
This seven year old boy was admitted to the children‘s home as an infant and 
diagnosed HIV positive at the age of three months.  He was admitted to hospital 8 
times prior to initiation of ART, for the management of pneumonia, gastroenteritis, 
and severe fungal rashes.  His CD4 count before treatment was 505 and 715 one 
year after treatment.  He was initiated on ART at the age of five as a subject of a 
research study.  The treatment regime was AZT, NVP, and 3TC.  There were no 
adverse effects to the medication and his health improved dramatically, with no 
further hospitalisations.  He was referred to the neuropsychiatric clinic with a one 
year history of hyperactivity, poor concentration, and severe aggression.  His 
caregiver was concerned that he barely completed homework tasks and was 
reading less fluently than in the past.  
 
There was a marked deterioration in the child‘s behaviour (increased aggression), 
after he was transferred from the children‘s home to a community home in a local 
township, requiring a change of school and adjustment to a social environment of a 
predominantly Xhosa speaking community.  He presented with disruptive behaviour 
characterized by severe aggression, mood lability, tearfulness, and agitation.  After 
several weeks, he failed to settle in his new environment and he was then 
transferred back to the children‘s home.  From there, he was transferred yet again to 
another community home nearby and placed back at his previous school.  













challenging with symptoms of restlessness and inattentiveness, which settled after 
he received stimulant medication.  However, he displayed markedly disturbed 
behaviour in relation to a particular caregiver, characterized by ambivalent 
interactions, at times intense to the point of possessiveness, and at other times 
hostile and overtly aggressive.  The caregiver‘s reaction to this was equally 
ambivalent, inconsistent and overtly hostile.  His behaviour was reported to be 
significantly more manageable, when the other caregiver (his primary caregiver), 
was on duty.  His mother is alive but she has maintained only erratic contact, which 
further distressed the child. 
 
Diagnoses of ADHD and an Adjustment Disorder were made.  Short-acting 
Methylphenidate was initiated at 5mg daily and increased to 20mg daily in divided 
doses, to which there was a positive response.  At this dosage, the formulation was 
changed to a long acting formulation.  A second medication, the antipsychotic agent 
Risperidone, was added after three months because of the persistence of severe 
aggressive outbursts (dose range 0,5mg - 1mg daily).  Subsequently his caregiver 
and his teacher both reported a positive response.  Risperidone was stopped after 6 
months, owing to excessive drowsiness and because his level of aggression had 
declined.  The child was seen regularly for individual counselling and home visits 
conducted to provide parenting input to both care workers.  His behaviour settled in 
the care of an alternative caregiver who interacted with him empathically and 
consistently. 
 
Case 3 (8 years, 3 months) 
 
Case 3, an 8 year old girl, was diagnosed HIV positive aged eleven months.  Her 
mother was alive but abused alcohol and provided erratic care.  She was removed 
and placed at the children‘s home as a toddler.  Her maternal grandmother 
maintained contact.  She presented with failure to thrive, persistent fever, coughing 
and generalized lymphadenopathy at the age of eleven months.  She was 
diagnosed with marasmic kwashiorkor and tested HIV positive.  There were four 
hospital admissions prior to initiation of ART, for the treatment of severe skin 
infections (molluscum contagiosum, candidiasis and abscesses) and gastroenteritis.  
Treatment was initiated at the age of six years, at Red Cross Children‘s Hospital, 
with d4T, 3TC, and Kaletra.  Her CD4 count was 411 at initiation and 1259 a year 
later.  The child was referred for a psychiatric assessment as she presented with 













were also complaints of being inattentive and unfocussed in the classroom, with 
poor academic performance.  She fulfilled criteria for a diagnosis of ADHD, 
inattentive type and was initiated on a trial of short acting Methylphenidate, with 
good response.  Because of her low weight and poor appetite the dosage was 
maintained at 15mg daily.  She settled well in her grandmother‘s care and continued 
to attend clinic visits. 
 
Case 4 (10 years, 8 months) 
 
Case 4 was orphaned and placed at the children‘s home as an infant.  Date of HIV 
diagnosis was not recorded in the hospital records.  She was a healthy infant and 
child with no hospitalizations or illnesses.  She was admitted on to the ARV study at 
Groote Schuur Hospital and commenced on ART, aged nine.  The treatment regime 
was AZT, 3TC, and Nevirapine (NVP).  She was hospitalized after she developed a 
toxic skin rash in reaction to NVP and she was changed to Kaletra (KAL).  CD4 
count before Art was 319 and 755 one year later. 
 
She was ten years old at the time of the assessment and presented with three 
episodes of possible visual hallucinations.  She saw a woman in her room at night, 
but this resolved when the furniture was rearranged in the bedroom.  There were no 
other emotional symptoms and she functioned well socially and coped academically 
at a mainstream school, except for problems with arithmetic.  Neurological 
examination revealed microcephaly and generalized brisk reflexes (no focal signs) 
and there was no EEG abnormality.  She continued to function well and was 
adopted by her host family and immigrated with them to the United Kingdom. 
 
Case 5 (11 years, 1 month) 
 
Case 5 was an eleven year old girl who was admitted to the children‘s home as an 
infant, after her mother died.  She was born and diagnosed HIV positive at Somerset 
Hospital.  She was hospitalized three times during early childhood for severe otitis 
media and gastroenteritis.  She was initiated on ART aged eleven as part of the 
research study.  Her CD4 count before treatment was 328 and 889 one year after 
treatment started.  Viral load was undetectable one year post treatment.  The initial 














She was referred to the Neuropsychiatric Clinic as she had experienced several 
episodes of visual hallucinations over a period of six to eight months associated with 
severe behavioural disturbances such as undressing herself, severe aggression, 
confusion and uncooperativeness.  There were no other psychotic symptoms 
present and no observed alterations in level of consciousness or drowsiness 
following the episodes.  She also displayed challenging behaviour such as 
disruptiveness and uncooperativeness (towards caregivers and teachers), in 
addition to severe restlessness and inattention for years prior to the current 
presentation. 
 
Her caregiver reported that she was intermittently not orientated to the day and date 
and that her reading had deteriorated prior to the referral to the clinic.  There was a 
scholastic decline to the extent that she was transferred to an ELSEN school.  
However, once there it was felt that she should be transferred back to the 
mainstream school.  She made minimal progress academically in mainstream 
school, requiring yet another transfer back to the ELSEN School.  She was referred 
for a neurological assessment to exclude complex partial seizures.  An EEG 
(electroencephalogram) test was abnormal and showed left frontal and left 
centrotemporal foci.  CT Brain and MRI (done later due to persistence of symptoms 
and an impression of neurocognitive decline) were normal.  In addition, she 
presented with symptoms compatible with a diagnosis of ADHD.  She was 
commenced on a course of the anti-epileptic, Sodium Valproate (800mg daily in 
divided dosages).  The episodes of visual hallucinations abated but there were 
ongoing problems of severe restlessness, inattention, and aggression.  A second 
medication, Methylphenidate was added after six months, to which there was a 
partial response (starting dosage 10mg, to maximum of 30mg daily).  At this dosage, 
the formulation was changed to a long acting preparation.  She continued to display 
behavioural difficulties and intermittently appeared to be confused.  A lumbar 
puncture was therefore performed in order to establish the CSF viral load, which 
was undetectable.  Neurological examination was normal.  The neurologist added a 
diagnosis of a seizure disorder (complex partial seizures).  The impression at this 
stage was that the clinical picture might have indicated early HIV encephalopathy 
(she fulfilled two of the three criteria of neurocognitive, behavioural and motor 















Case 6 (11 years 8 months) 
 
Case 6 was removed from his mother‘s care due to neglect, as an infant and placed 
at the children‘s home.  He was diagnosed HIV positive as an infant.  There were 13 
admissions prior to initiation of ART for numerous illnesses such as diarrhoea, 
pneumonia, and severe infections (candida infections, episode of septicaemia).  He 
was started on treatment as part of the research study and initiated on AZT, 3TC, 
and NVP.  The NVP was stopped (and changed to KAL) after he developed drug 
induced hepatitis.  His CD4 count before treatment was 538 and 825 one year later, 
post ART.  Response to ART was positive with no further illnesses and 
hospitalisations. 
 
He was initially assessed, age ten months, by the neurodevelopmental service at 
Red Cross Hospital and scored within the range of mild global delay.  He was 
followed up by the neurodevelopmental service and diagnosed with ADHD at the 
age of five.  He was referred to the psychiatric service in 2001 at the age of eight, 
because of aggression, oppositional behaviour, and a poor response to stimulant 
medication (Methylphenidate).  He was diagnosed with Oppositional Defiant 
Disorder.  He was assessed at the Neuropsychiatric Clinic at the age of twelve 
because of worsening of aggressive outbursts, oppositional behaviour, defiance, 
and verbal abuse.  Behaviour problems appear to have escalated after visits to his 
biological father broke down and contact was made with his biological mother, with 
whom he had a poor relationship.  He presented with increasing aggression, verbal 
abuse, and oppositional behaviour.  The current deterioration in his behaviour was 
again precipitated by his distress at being placed in the care of his aunt.  His 
biological mother lived with the aunt as well, was HIV positive and abused alcohol.  
His relationship with his mother (who denied her own and his HIV status) was 
distant and ambivalent.  He struggled to adjust to the changed economic 
circumstances and different religion of his family of origin (Muslim faith), as he had 
been raised as Catholic at the children‘s home.  
 
He was diagnosed with an Adjustment Disorder, in addition to a previous diagnosis 
of Oppositional Defiant Disorder.  Neurological examination and EEG were normal.  
He was commenced on the neuroleptic medication, Risperidone (dose range 0,5mg 
- 1,5mg daily), for the management of severe aggression prior to the assessment at 













same dosage of 1,5mg daily.  He was referred to a social skills group.  The level of 
aggression abated but he continued to display compositionality, verbal aggression 
and disregard for the adults at the time of his placement with his family.  He 
underwent neurocognitive testing in 2001 at the age of 7years and 9 months.  There 
were concerns about his fluctuating academic performance, which was possibly 
driven by anxiety and attention/concentration difficulties.  It was felt that a baseline 
level of neurocognitive functioning would better inform decisions about school 
placement and further management.  The test administered was the JSAIS, which 
revealed an intelligence quotient in the lower limits of the low average range (IQ 80-
89).  Repeat neurocognitive testing at the age of twelve revealed intellectual 
functioning in the mild to moderate range of intellectual functioning, representing a 
decline over time.  He was placed at an ELSEN school and subsequently 
permanently placed with his aunt and lost to follow up. 
 
Case 7 (12 years, 4 months) 
 
Case 7 was referred for placement to the children‘s home as a child, for terminal 
care.  She was diagnosed HIV positive at the age of two and presented early on with 
numerous illnesses (pneumonia, wasting syndrome, tuberculosis, seizures and 
urinary tract infections), resulting in eight hospitalizations prior to initiation of ART.  
ART (a regime of 3TC, AZT and Efavirenz) was started at the age of ten during a 
period of hospitalization.  The CD4 count pre and post ART were 180 and 310 
respectively. 
 
She was ten years old at the time of referral to the Neuropsychiatric Clinic.  She 
presented with episodic vomiting, suspected to be emotionally based, as the 
impression was that she was trying to achieve hospitalization via self-induced 
vomiting.  Neurological examination and EEG were normal.  She struggled to cope 
with neurocognitive testing, as she was ill at the time, and scored below 50 for full 
scale IQ, which was felt to be an inaccurate reflection of her intellectual ability.  The 
vomiting turned out to be a symptom of a gastrointestinal condition, which resulted 
in her becoming seriously ill.  The outcome of the psychiatric assessment was that 
the symptoms were related to her medical condition.  She was followed up for six 















Case 8 (13 years, 0 months) 
 
Case 8 was born prematurely and diagnosed as an infant with congenital syphilis 
and Foetal Alcohol Syndrome (FAS).  He was abandoned at a local hospital in the 
Northern Cape.  His mother died soon afterwards.  There is no known history of 
mental illness in the family.  He was diagnosed HIV positive at the age of two.  This 
was after a stormy first two years of life, with admissions for meningitis, 
gastroenteritis, and severe skin infections.  His CD4 count before starting ART was 
286.  He was admitted to the research study and initiated on treatment at the age of 
eleven years (with a regimen of AZT, 3TC and NVP).  The NVP was stopped as he 
developed abnormal liver functions and KAL initiated.  His CD4 count one year after 
ART was 441, with further admissions for meningitis and a severe skin abscess.  His 
health improved subsequently with no further admissions. 
 
He was referred for a psychiatric evaluation initially at the age of seven years for 
problems of aggression, mood lability, and oppositional behaviour and a trial of 
Methylphenidate was initiated with poor response.  He was re-referred, aged 
thirteen, to the Neuropsychiatric Clinic.  At the time, he was attending a special 
school.  Eighteen months prior to the recent clinical presentation, he was reunited 
with his family and made visits to the Northern Cape, accompanied by his caregiver, 
during the school holidays.  The plan was that this would eventually become a 
permanent placement.  He struggled, however, to adjust to the visits and became 
distressed if left alone without his caregiver.  The current referral was precipitated by 
a sudden deterioration in mood (depressive symptoms), suicidal ideation, and two 
suicide attempts (suffocation, electrocution).  The precipitating event was that he 
was informed two months prior to the presentation that he would be leaving the 
children‘s home permanently and that he would be placed with extended family.  
The mental state examination done during his initial visit described a shy, reticent 
boy.  He was mildly anxious and appeared depressed.  He reported depressed 
mood and suicidal ideation.  There were no psychotic symptoms.  Neurological 
examination was normal except for microcephaly, but the EEG was abnormal and 
showed right hemispheric spike and wave discharges.  There was no history of 
observed seizures.  MRI scan of the brain was normal.  He was initially commenced 
on Sodium Valproate (a dosage of 600mg daily, in divided dosages).  After initiation 
of the anticonvulsant, he became more contained with no further episodes of 













counselling sessions.  A course of the antidepressant, Fluoxetine, was added after 
three months.  This was stopped after he presented with an episode of mania, two 
months later.  Medication management consisted of a combination of Sodium 
Valproate and Risperidone (dose range 1-3mg daily), with a resolution of symptoms.  
He subsequently presented with a manic episode a year later, despite compliance 
with medication.  In between relapses, he was contained but reported episodes of 
‗funny feelings‘ and fleeting visual hallucinations, which was accompanied by 
observed periods of an altered level of consciousness and postictal drowsiness.  
The episodes resolved after the medication dosage was increased to 1000mg daily 
(in divided doses).  Episodes were interpreted as being epileptic in nature.  Subtle 
neurocognitive problems also became evident during follow up: he had problems 
with short term memory and basic arithmetic.  His CSF viral load was undetectable. 
 
His neurocognitive ability was assessed at fifty six and eighty months respectively, 
while not receiving ART.  He was referred for a developmental assessment because 
of suspected global delay, as well as problem behaviours such as aggression, 
defiance, and poor sleep.  The test used was the Griffiths Developmental Test.  The 
result of the test done at fifty six months indicated that he was functioning at the 
level of forty eight months for gross motor, fine motor, and language skills, and forty 
two months for personal/social development, indicating borderline developmental 
delay.  The test was repeated at eighty months with scores of sixty six months for 
gross motor skills (Developmental Quotient (DQ) 82%), sixty months for fine motor 
(DQ 75%) and fifty four months for language (DQ 85%) and thirty six months for 
personal/ social development.  On the basis of the test result an application was 
made to a special school for learners with moderate intellectual disability. 
 
Case 8 was subsequently tested again at the age of thirteen years and scored in the 
mild to moderate range of intellectual ability, demonstrating a decline in 
neurocognitive functioning. 
 
Case 9 (13 years, 6 months) 
 
Case 9 was admitted to the children‘s home as an infant in a severely malnourished 
state and with a maggot infestation of the testes.  His mother had abandoned him at 
Somerset Hospital.  His mother subsequently died and contact was lost with his 
biological family for a number of years.  His early years were characterized by nine 













meningitis, pneumonia, gastroenteritis, shingles, and chickenpox.  He presented at 
the age of three years with meningococcal meningitis.  He was subsequently 
diagnosed with HIV encephalopathy.  A CT scan of the brain performed at the time 
showed two areas of white matter hypodensity in the right frontal region.  He was 
referred for neuropsychological testing to establish his baseline level of 
neurocognitive functioning in 2002, at the age of 10 years and 8 months.  At the time 
he was not on ART.  He presented with behavioural difficulties such as aggressive 
outbursts, was reported to be rebellious and disobedient, and had begun to struggle 
with numeracy and reasoning tasks.  He had lost a significant amount of weight 
during the previous year.  Neurologically, he suffered a mild speech impediment and 
walked with a spastic gait.  The neuropsychological battery included tests of motor 
functioning, attention, language, visuographic ability, and memory.  In addition an 
SSAIS was administered.  The neuropsychological tests revealed problems with fine 
and gross motor functions, motor slowing affecting speed of visual tracking and 
speed of output of tasks.  His vocabulary, verbal reasoning skills, auditory memory, 
and planning were good, but his visuospatial abilities were assessed as low 
average.  The result of the SSAIS showed an intelligence quotient in the average 
range. 
 
He was initiated on ART (AZT, NVP and 3TC) at the age of eleven as part of the 
research study.  His CD4 count before ART was 432 and 776 one year after 
initiation of treatment.  His health improved dramatically with no further admissions.  
He was thirteen years old at the time of referral to the neuropsychiatric clinic, having 
been initially referred to psychiatric services, aged nine, for social/communication 
difficulties, mood lability, aggression, restricted interests and flights into a fantasy 
world.  On interview, he was aloof and displayed a pedantic, rigid cognitive and 
conversational style suggestive of Asperger‘s disorder.  However, full criteria for 
Asperger‘s Disorder were not met.  He was subsequently diagnosed with Pervasive 
Developmental Disorder, not otherwise specified (PDD-NOS).  He was re-referred 
because of increasing mood lability and aggression.  The precipitating event was the 
disclosure to the patient that he would not be adopted by his host parents and that 
he would continue to be resident at the children‘s home.  An additional stressor was 
that the children‘s home made contact with his biological family and arranged 
weekend visits, which he found very difficult.  A visit was arranged to the Eastern 
Cape to meet his grandfather and visit his mother‘s grave, both of which he 













locally.  Instead, he insisted on being adopted by his host parents, who unfortunately 
were not able to do so, as they planned to emigrate.  Furthermore, they feared, as 
an older couple, that his increasingly challenging behaviour would become 
unmanageable.  He denied his HIV status and that he was black, stating that only 
black people were HIV positive.  He would take flight into a fantasy world as a 
character in ‗Peter Pan‘.  He refused subsequent contact with family and persistently 
and at times coercively insisted on contact with the host parents.  There were no 
behavioural problems at school, but he was described as ‗odd and aloof‘, with no 
meaningful friendships with peers.  There were no academic problems reported.  He 
was initially diagnosed with an Adjustment Disorder and the diagnosis of PDD-nos 
was upheld.  However, his mood deteriorated over the next few months at which 
point he fulfilled criteria for a Major depressive Episode (MDE).  There was a poor 
response to Fluoxetine (which was increased to a maximum dose of 20mg daily) 
with ongoing irritability, aggression, and mood lability.  There were no features to 
suggest a manic episode or symptoms suggestive of a psychosis.  A trial of Sodium 
Valproate (700mg daily in divided doses) was initiated after the Fluoxetine was 
stopped, with an improvement in mood. 
 
Subsequent testing at the Neuropsychiatric Clinic, once again demonstrated an 
average level of neurocognitive functioning and resolution of his neurological 
symptoms suggesting a positive impact of ART on the HIV encephalopathy.  
However, he continued to display aggressive outbursts, oppositionality, and extreme 
egocentricity during challenging interpersonal situations, necessitating a trial of 
Risperidone (up to a maximum dose of 3mg daily), with only a partial response.  A 
brief trial of Haloperidol was equally ineffective.  Subsequent to this alternative 
placement was sought and he was placed at another children‘s home, where the 
problems persisted, necessitating yet another placement.  His host parents 
remained in contact. 
 
The following section provides further details of the neuropsychiatric assessments 
and follow-up of the children.  Relevant information obtained from the medical 
records will be described.  The chapter will conclude with a brief summary, which 
will collate findings from the clinical case series, with information extracted from the 















 2.5.1 Psychiatric Evaluation 
 
2.5.1.1 History of presenting complaints 
 
The primary reason for referral to the Neuropsychiatric Clinic was for the 
assessment and management of emotional and behavioural difficulties that had 
emerged during the period following initiation of ART.  The majority of children were 
referred for problems of aggression, hyperactivity/inattention, and mood 
disturbances, including mood swings, irritability, depression with suicidal ideation 
and intent.  Two children presented with visual hallucinations (see table 1).  There 
were also concerns about the children‘s academic progress: a number of caregivers 
felt that the children were not able to produce homework of a standard expected of 
them and were generally not achieving basic numeracy and literacy skills.  The 
difficulties around homework were compounded by attention difficulties as well as 
uncooperative behaviour, particularly from the boys.  Some of the children were felt 
to have lost reading and writing skills previously acquired.  There was a further 
concern that some of the children‘s disruptive behaviour in the classroom was 
compounded by their academic difficulties.   
 
Caregivers believed that the academic demands and standards at mainstream 
schools exceeded the children‘s ability, further compounding the stress experienced 
in the school environment.  There were fewer concerns about the academic 
progress of children placed at ELSEN schools and fewer reports of challenging 
behaviour by their teachers.  There was a consensus that all the children, except 
one, struggled with numeracy.  Three children underwent neurocognitive 
assessments at a younger age, prior to referral (see table 5).  All three were boys 
and were tested more than two years prior to referral to the neuropsychiatric clinic.  
Tests used were the JSAIS, SSAIS, and the Griffiths Developmental Test.  One 
child, subsequently diagnosed with HIV encephalopathy, underwent a 
neuropsychological battery as he had begun to struggle with numeracy and 
reasoning tasks.  He had also demonstrated problems with expressive language 













Table 1:  History of Presenting Complaints 
Cases 1 2 3 4 5 6 7 8 9 
Age at 
Referral 
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2.5.1.2 Collateral information obtained from educators 
 
Information was obtained from educators via regular questionnaires.  Face to face 
interviews were conducted where school visits were undertaken.  The 
questionnaires included questions about classroom behaviour (level of activity, 
inattention, aggression, social interaction, anxiety/mood) and academic progress.  
Information obtained revealed concerns mostly about problem behaviours such as 
restlessness, poor concentration, aggression, social and interpersonal difficulties.  
There was an impression that the children were immature and struggled to maintain 
peer relationships with children of similar age.  Questionnaires revealed that all the 
children, except one (case 9) were not performing academically on a par with peers 
and required remedial input or additional input for all areas of work.  There were 
particular concerns about three children, (cases 2, 5 and 8) who presented with 
more marked behavioural disturbances in the classroom environment.  This included 
behaviour such as aggression, uncooperativeness, hyperactivity and inattention.  
The schools responded with frequent letters to the guardians and requests for 
interviews with the caregivers.  None of the children were excluded from the study 
because of unacceptable behaviour. 
 
2.5.1.3 Common themes that emerged following interviews with the children and 
caregivers 
 
a) Leaving the children‘s home 
 
A number of children had been reunited with either their biological parent/s or 
families.  Some of them had been permanently placed or were being prepared for 
placement.  Those who could not be placed were subsequently accommodated at a 
community home run by the institution.  The reasons why children could not be 
placed back with their biological families is that some of the parents were deceased, 
extended family members were not able to care for a child or no ARV‘s were 
available at the local clinic or hospital in more remote rural areas.  The process of 
placement evoked anxiety about leaving the familiar environment of the children‘s 
home and particularly familiar adults and attachment figures.  One child (case 8) 
threatened to kill himself rather than leave the children‘s home and later attempted 















b) Cultural and language issues 
 
All the children had been raised in an English-speaking environment; because of 
this, they had not acquired the use of any indigenous language or Afrikaans.  Some 
of the children, therefore, found it extremely difficult to communicate with Xhosa 
speaking families when they visited over weekends and holidays.  They had also 
become alienated from the religion and cultural norms of their families as they were 
raised in a westernized, Christian (Catholic) environment.  These issues further 
complicated the transition to life in the community and they have contributed to the 
children‘s experience of alienation from the new environments to which they have 
been exposed.  
 
c) Economic issues  
 
Families of origin lived in economically disadvantaged circumstances, significantly 
less privileged than the lifestyles the children had become accustomed to at the 
children‘s home and via volunteer host families.  Some of them struggled to adjust to 
this.  Some of the biological family members unfortunately placed the children and 
the home under pressure to provide money or goods that were not affordable, as a 
condition of contact.  This cast doubt upon the motivation for receiving the children 
back and fuelled concerns about whether the placement would be sustained, once 
financial or material support ceased. 
 
d) Developmental phase of adolescence 
 
Three of the children were entering adolescence (aged twelve and thirteen).  Anxiety 
was expressed about having to leave the children‘s home when they turned thirteen 
years old.  A wish to ―stay small like Peter Pan‖ was expressed by one of the 
children (Case 9).  There was a growing awareness of their relatively small stature 
and delayed puberty compared to peers and a more realistic sense of the 
implications of being HIV positive.  Concerns were expressed about the stigma of 
HIV and issues of confidentiality.  One of the boys, for example, became reluctant to 
be transported in the bus belonging to the children‘s home, as he believed that 













provided AIDS hospice services.  Sexual acting out and curiosity was more 




All of the children had been informed about their HIV positive status from a young 
age (under five years old).  The younger children rarely expressed their opinion 
about this and appeared to adjust easily to the frequent hospital visits and 
medication with little outward expression of distress.  However, the older children 
appeared to be more aware of the implications of their HIV status and would either 
express concerns that they might become ill and die (case 8) or deny their HIV 
status.  Denial of HIV commonly was linked with a denial of their race, claiming that 
they themselves belonged to another racial group and that HIV was a condition 
exclusively suffered by black people. 
 
f) Interpersonal/relational problems  
 
Some of the children struggled to maintain positive relationships with peers and 
adults.  The relationships with some of the caregivers were intense and ambivalent.  
Interactions were sometimes described as being contained, but at other times, 
provocative, hostile, and overtly aggressive to the extent of committing physical 
attacks on the caregivers.  Likewise, a number of the interactions between the 
children were equally volatile, with frequent arguments and aggressive outbursts.  
This was in stark contrast to the rest of the children in the home (HIV positive, non-
referred group) who were able to sustain more positive relationships with adults and 
peers. 
 
g) Behaviour Management 
 
Most of the caregivers were concerned about their ability to contain difficult 
behaviour in the children, and to set consistent limits and boundaries.  The adults‘ 
management of the children was inconsistent and there was not enough effective 
communication across shifts.  Consensus about the imposition of more consistent 
rules, limit setting, and boundaries was difficult to achieve.  It was strongly felt that 
the children were managed differently on different shifts and by different adults, 













appeared to deliberately play one adult up against the other.  This was confirmed in 
that the children‘s behaviour was particularly difficult on certain shifts and when in 
the care of certain caregivers.  One of the caregivers expressed extreme emotional 
distress about being attacked (bitten, hit, scratched) by a child (case 2), and 
struggled to manage his difficult behaviour in an emotionally detached manner.  
Caregivers who felt more confident about their parenting skills, reported fewer 
behavioural problems by the children in their care and generally believed 
themselves to be more successful in managing difficult behaviours.  All the 
caregivers expressed the need for regular parenting input and the need for more 
coherent and consistent strategies for managing problem behaviours.  Some 
caregivers were of the opinion that there was an inappropriate reliance on 
medication to contain the behaviour rather than addressing inconsistent parenting 
practices, which they believed, drove some of the behaviour. 
 
2.5.1.4 Psychiatric Diagnoses following psychiatric evaluation 
 
The following diagnoses were obtained following psychiatric evaluation of the 
children referred: 
1. Attention Deficit Hyperactivity Disorder (ADHD) n=4.  Two children presented 
with the combined type ADHD, and another two with predominantly 
inattentive type ADHD.  One boy and one girl were diagnosed in each group. 
 
2. Mood Disorder due to a General Medical Condition (GMC) n=1.  The 
underlying medical condition was a possible seizure disorder associated with 
early HIV encephalopathy:  the child presented with two of the three criteria 
of behavioural, neurocognitive and motor impairments needed for diagnosis. 
 
3. Mental Disorder not otherwise specified (NOS) due to a GMC n=1.  The 
patient presented with episodes of disturbed behaviour, visual hallucinations, 
and confusion.  While a definite history of observed seizures was not 
provided, a seizure disorder was a possible diagnosis on the basis of the 
general history and positive response to an anticonvulsant.  The aetiology 
was unclear but may have been an early HIV encephalopathy (the child 
fulfilled two of the three criteria of behavioural, neurocognitive and motor 














4. Adjustment Disorder n=3.  Adjustment Disorder diagnoses was made in 
three of the children as they presented with significant emotional and 
behavioural difficulty in reaction to a proposed plan to change their 
placement.  In the case of two of the children, it was to place them with their 
biological families and in one of them; a plan by the host family to adopt him 
was reconsidered. 
 
5. Pervasive Developmental Disorder, not otherwise specified (PDD NOS) n=1. 
 
6. Oppositional Defiant Disorder (ODD) n=2 
 
7. Major Depressive Episode (MDE) n=1.  A diagnosis of MDE was made in a 
thirteen year old boy who had been previously diagnosed with PDD NOS.  
There was a longstanding history of mood lability, tearfulness, and irritability, 
but he presented with additional symptoms of depressed mood, social 
withdrawal, loss of interest in usual activities and suicidal ideation.  
 
Two children did not receive psychiatric diagnoses.  One of them presented with a 
history of being ‗dreamy‘, poor concentration, and having seen ‗visions‘ which 
resolved spontaneously.  There were no symptoms of anxiety and no seizures were 
observed.  Neurological examination and investigations were normal.  A diagnosis of 
ADHD, inattentive type, was considered but she did not meet the full criteria at the 
time.  The other child presented with a history of possible self-induced vomiting and 
regressed behaviour, in the absence of other emotional symptoms.  Evaluation 
revealed no psychological reason for the vomiting in this seriously physically ill child.  
The clinical presentation was then assessed as being related to her medical 
condition. 
 
2.5.1.5 Other Diagnoses Considered 
 
1. Schizophrenia/Psychotic disorder:  The two children who presented with 
visual hallucinations did not display other psychotic symptoms such as 
delusions, thought disorder or other perceptual disturbances. 
 
2. Bipolar Disorder: A number of children presented with significant mood 













depressed mood.  Case 8 presented with manic symptoms, an elevated 
mood, euphoria, decreased sleep, increased appetite, and hyper-sexuality.  
A diagnosis of Bipolar Disorder was considered but as this child had an 
abnormal EEG (temporal lobe focus), a diagnosis Mood Disorder secondary 
to a GMC was made. 
 
3. Anxiety disorders:  A number of children presented with significant anxiety 
symptoms and expressed distress about a number of issues such as leaving 
Nazareth House, growing older and their HIV status.  The aggression and 
‗acting out‘ behaviour appear to have been driven by underlying anxiety as 
the children struggled to articulate their concerns that were expressed via 
their negative behaviour.  Several of the children presented with anxiety 
symptoms such as excessive worry, irritability, and fears of abandonment.  
None of the presentations, however, fulfilled criteria for the DSM IV diagnosis 
of a Generalized Anxiety Disorder that requires additional symptoms such as 
restlessness, fatigue, poor concentration, muscle tension and sleep 
disturbances.  
 
4. Attachment Disorders:  Disturbances of attachment were felt to drive some of 
the behaviours observed.  For example, the entire cohort displayed 
indiscriminate friendliness and lack of boundaries towards unfamiliar adults, 
commonly observed among institutionalized children.  Except for case 5, the 
girls appeared to be more securely attached and seemed to have 
relationships that are more positive with their caregivers and related to adults 
in a more consistent manner.  The boys, however, tended to relate in a more 
ambivalent manner, vacillating between positive interactions and volatile, 
provocative behaviour. 
 
2.5.1.6 Clinical management 
 
All the children attended a monthly follow up clinic visit.  They were seen individually 
and with their caregivers.  Behaviour-based interventions were implemented and 
explained to the individual child and caregiver.  Monthly case discussions were also 
held with caregivers, Social Workers and the treating Paediatrician at the children‘s 
home.  These home visits were conducted at the main house and the cottages of 













environment and the quality of their relationships could be assessed.  A further 
aspect of the home visits was that parenting input could be given to the staff 
members who were struggling with managing the children‘s behaviour, but who 
were not able to attend the clinic visits. 
 
Table 2:  The Diagnoses and Biopsychosocial Management of the Children Assessed. 
Case Diagnosis Psychological  
Management 








*Methylphenidate (MPH) short acting (SA) 15mg 
Two divided dosages of 10mg at 7.30am and 5mg at 11am 
Medication initiated 6 months after initial assessment, due to 
young age 




MPH (SA) 5-20mg 
Divided dosages (7.30am, 11am, 2pm) 
*MPH Long acting (LA) 20mg morning 
Risperidone     0,5-1mg 








Two divided dosages of 10mg at7.30 am and 5mg at 11am 
4 No diagnosis Monthly clinic 
visits 
Followed up for six months 







*Sodium Valproate    400mg 2x daily 
MPH (SA) 10-20mg daily 
MPH SA stopped and LA commenced 




?  ADHD 
Social skills group 
Parental guidance 
Risperidone 
0,5-1mg daily  
Lost to follow up 
7 No diagnosis No diagnosis  
8 Mood disorder 
2˚ GMC 





Fluoxetine    20mg daily 
Manic episode precipitated after six weeks.  Stopped 
*Sodium Valproate    400mg am/600mg pm 
*Risperidone1-3 mg daily 
Dosage of Risperidone reduced to 1mg when stable 
9 PDD NOS 
MDE 






Fluoxetine    20mg daily 
Poor response to Fluoxetine, so stopped after twelve weeks 
Haloperidol     0,5-1 mg night 
Poor response and Extrapyramidal side effects (EPSE) on 
Haloperidol, so stopped after one month 
*Sodium Valproate     300mg/400mg 
*Risperidone     1-3 mg 


















a) Psychotherapeutic Interventions 
 
i. Individual supportive counselling:  Two children, both males, were referred to 
a nurse therapist for fortnightly psychotherapy/counselling sessions within 
the service. 
ii. Social skills group for preadolescents:  Three children (cases 6,8 and 9), all 
males, were referred to a social skills group.  Indications for referral were 
that all three boys struggled to relate to peers, had difficulties managing their 
anger and could not resolve conflict in a pro-social manner.  The pre-
adolescent group consists of twelve weekly sessions attended by about eight 
mixed gender children.  Children receive social skills training, life skills, 
anger management, and understanding of feelings.  Those who attended 
coped well and related to other members of the group.  However, all three 
chose not to disclose in the group that they lived in a children‘s home and 
that they were HIV positive. 
iii. Parental guidance:  the case manager provided Parental guidance to 
caregivers on an individual basis during the clinic and the home visits.  
Intervention that is more intensive was provided by the Clinical Social 
Worker employed by the children‘s home by means of regular support 
groups for caregivers. 
 
b) Medication Management  
 
Four children (three males, one female) were commenced on psychotropic 
medication shortly after the initial psychiatric assessment.  Another three children 
were initiated on medication on later follow up, within the first year after assessment.  
Indications for medication were for the management of severe aggression, for 
depression, which was unresponsive to psychotherapy, and for ADHD symptoms.  
Medications prescribed were stimulants (n= 4), atypical antipsychotics (n= 4), typical 
antipsychotics (n=1), and antidepressant medication (n=2).  Two children were 
medicated with anti-epileptic medication (Sodium Valproate), after EEG tests were 
found to be abnormal and, in addition, to treat a manic episode.  The lowest 
effective dosages were prescribed, particularly in the case of a five year old child, 
and in two patients with low body weight.  Standard dosages were achieved in most 
instances and were well tolerated, with very few adverse side effects (only one child 













stimulant medication was favourable, with few adverse side effects.  Academic 
performance, however, did not improve substantially after the initiation of stimulant 
medication.  Response to being medicated with Risperidone for the treatment of 
aggression was partial, with persistence of aggressive behaviours.  Response to 
Sodium Valproate was positive with cessation of visual hallucinations and episodes 
of confusion in one patient and the reduction and control of manic symptoms in 
another.  Treatment with a SSRI, Fluoxetine, appeared to have precipitated a manic 
episode in the latter patient and failed to achieve amelioration in depressive 
symptoms in another (despite an adequate trial of twelve weeks). 
 
 2.5.2 Neurocognitive assessments 
 
 All the children were referred to a Clinical Psychologist for cognitive assessments 
as part of the evaluation at the Neuropsychiatric Clinic.  Tests used were the Junior 
South African Individual Scale (JSAIS) and the Senior South African Individual 
Scale-Revised (SSAIS-R).  Intelligence Quotients (IQ) were obtained via Verbal IQ 
(VIQ) and Performance IQ (PIQ) scales to reach a Full Scale IQ score (FSIQ) to 
reflect the child‘s performance. 
 
Description of cognitive tests: 
 
a) The JSAIS was developed in 1979.  It is a standardized test to assess the 
cognitive abilities as well as the functional strengths and weaknesses of 
South African Children, during the first year of school.  The test is generally 
utilized for children aged six to eight years.  There are twenty two subtests, 
which can be combined to form a verbal, performance and full scale 
intelligence quotient (Tlali T 2004).  
 
b) The SSAIS-R is a test to measure general intellectual ability of children aged 
seven to sixteen years.  It consists of five verbal and four non-verbal 
subtests, the composites of which provide scores for verbal, performance 
and full scale IQ.  A ‗Socio-economic Disadvantagement Scale‘ (SED 




















Three children scored in the average range, one in the borderline, and four in the 
mild intellectual disability range (two mild to moderate) and one in the moderate 
disability range.  Unfortunately, most of the children were not previously tested so it 
was not possible to compare results with previous tests.  Of those children 
previously tested, there was a decline in case six‘s score from the low average to 
mild intellectual disability range.  Case eight‘s score also fell from borderline 
intellectual ability at 56 months to mild intellectual disability at thirteen years of age.  
Case nine appeared to have maintained intellectual functioning in the average range 
and subjectively showed improvements in motor functioning. 
 
Management of academic problems: 
  
Two children attended an ELSEN school prior to the evaluation.  An application was 
made on behalf of four children for placement in a special school.  Reasons for 
referral were poor academic performance in the mainstream school, attention 
problems, hyperactivity, and negative behaviours (cases 2, 5, 6, 9).  Three children 
continue to attend a mainstream school and only one has continued to perform 
academically on a par with peers.  A request was made for remedial input at the 















Table 3: The neurocognitive Profile of the Children Tested 
Case 1 2 3 4 5 6 7 8 9 








5 years  
1 month 
7 years  
1 month 
8 years  
3 months 
10 years 
 8 months 
11 years  
1 month 
11 years  
8 months 
12 years  
4 months 
13 years  
O months 
13 years  
6 months 
Test JSAIS JSAIS SSAIS-R SSAIS-R SSAIS-R SSAIS-R SSAIS-R SSAIS-R SSAIS-R 
VIQ 80 68 65 86 61 58 50 55 107 




































Age at prior 
assessment 
N/A N/A N/A N/A N/A 10 months 
7 years 9 months 
N/A 4 years 8 months 
6 years 8 months 
10 years 8 months 

















battery:  fine and gross 
motor problems, motor 
slowing affecting speed 
of visual tracking and 
speed of output of 
tasks. 
Good vocabulary, verbal 
reasoning skills, 


















 2.5.3 Neurological assessment 
 
A Paediatric Neurologist on referral to the Neuropsychiatric Clinic assessed all the 
children.  The children were initially assessed by the psychiatric team, then referred 
to the Neurologist for an assessment and EEG tests.  Further neurological 
investigations such as neuroimaging, or lumbar puncture were undertaken when 
clinically indicated. 
 
Eight out of the nine children appeared to be asymptomatic from a neurological 
perspective.  One child (case 9) presented with motor coordination deficits, 
visuospatial difficulties and a spastic gait, which appeared to have resolved after 
ART was started.  Another child (case 5) presented with episodes of markedly 
disturbed behaviour characterized by visual hallucinations, aggression, and bizarre 
symptoms such as undressing herself and throwing herself to the ground.  
Caregivers did not observe any alterations in her level of consciousness, nor 
confusion, and the episodes were not followed by a period of drowsiness.  It was not 
possible to ascertain reliably whether there was a period of amnesia for the 
episodes.  Case 8 presented with a sudden onset of depressed mood associated 
with suicidal ideation and two suicide attempts (by electrocution and hanging). 
 
CNS examination was normal in the majority of the children with no focal 
neurological signs elicited in any of them.  One child displayed brisk reflexes and 
was noted to be microcephalic.  Another child bore facial features compatible with 
Foetal Alcohol Syndrome (FAS) and was noted to be microcephalic. 
 
All the children underwent an awake EEG examination.  The EEG was normal in 
seven of the nine children.  Tests were abnormal in two cases: Case 5 displayed left 
frontal and left centrotemporal foci with generalized discharges and case 8 showed 
right hemispheric spike and wave discharges.  These two children (case 5 and 8) 
were then referred for neuroimaging tests (CT x1, MRI x2, which were normal, with 
no evidence of mass lesions or cortical atrophy. lumbar punctures were also 
performed in these two children in order to determine the CSF viral loads, which 














Two of the children obtained a diagnosis of a seizure disorder, of which one was 
diagnosed with HIV encephalopathy subsequent to the neuropsychiatric 
assessment.   
 
2.5.4 Review of the medical records of the children assessed at the 
neuropsychiatric clinic 
 
2.5.4.1 Tracking the records 
Information was obtained from the medical records of the two treating hospitals, 
Groote Schuur Hospital (GSH) and Red Cross Children‘s Hospital.  From the 
medical records, it appears that the children in the cohort were initially under the 
care of Red Cross Children‘s Hospital and then were transferred to the care of a 
paediatrician at GSH when funding became available for ART.  From the records, it 
appears that the children were still mostly managed at the Children‘s Hospital when 
they became ill and required hospitalization and they would attend the clinic at GSH 
for ART.  They also participated in the research study conducted at GSH.  Later on, 
the children were transferred and managed exclusively at GSH.  Currently all of the 
children attend the GSH Infectious Diseases Clinic but also attend specialized 
services (Psychiatry, Neurology, Dermatology, ENT, Occupational Therapy and 
Speech Therapy) at Red Cross Children‘s Hospital.  A multidisciplinary service to 
HIV positive children does not exist resulting in numerous attendances to different 
clinics at the two hospitals with numerous absences from school.  
 
2.5.4.2 First onset of medical illness 
Seven out of the nine children presented with a medical illness before the age of 
one year and eight out of the nine by the age of eighteen months.  Only one child 
was well until the age of three years and three months when she developed a skin 
condition (impetigo).  All the children presented with infections: 3 had chest 
infections, one had meningitis, 4 had skin infections and one, gastroenteritis.  Case 
7 presented with a pneumonia and kwashiorkor.  Skin infections tended to be more 
severe with extensive staphylococcus skin infections, impetigo, chicken pox, and 
ringworm.  Chest infections were the second most common, with pneumonias, 
tuberculosis, and protracted episodes of bronchiolitis and wheezing.  Case 8 was 
diagnosed with congenital syphilis and FAS prior to the onset of his first HIV related 
illness.  Four of the children became ill after the HIV diagnosis was made and 













Table 4:  The initial medical presentation of the children, prior to the diagnosis of HIV. 
Case DOB Onset of first illness Diagnosis Date of HIV diagnosis Onset of ART 
1 5/07/2000 22/03/01 
Age: 9 months  
Ringworm 
Eczema 
Not recorded 15/03/03 
2 5/07/98 8/01/99 
Age: 6 months  
Lower Respiratory Tract Infection (LRTI) 
Bronchiolitis 
07/10/98 06/03/03 
3 24/04/97 15/02/98 
Age: 10 months  
Gastroenteritis 05/08/97 26/02/04 
4 27/11/94 18/02/98 
Age: 3 years 3 months  
Impetigo Not recorded 4/04/03 
5 10/06/94 04/09/95 
Age: 15 months  
Pulmonary Tuberculosis (PTB) Not recorded 14/02/03 
6 11/12/93 17/12/94 
Age: 3 months  
Pneumonia 14/01/94 06/03/03 
7 18/04/93 22/10/93 




8 31/07/92 13/11/92 
Age: 5 months  
PTB 
Staphylococcus skin infection 
19/01/94 14/02/03 
9 22/02/92 04/08/92 
Age: 6 months  













2.5.4.3 Subsequent medical presentations 
All of the children, except for case 4, presented with frequent episodes of illness.  
Case 4 was in good health bar one episode of an upper respiratory tract infection, a 
skin rash (Impetigo), and a middle ear infection (Otitis Media).  Infections with well-
known bacterial and viral organisms were the most frequent clinical presentation, 
but they tended to be more severe and had a more protracted course.  Skin 
infections were the most common, followed by gastroenteritis and respiratory tract 
infections (Pulmonary Tuberculosis, Pneumonias).  None of the children developed 
severe infections with opportunistic organisms, or neoplastic conditions.  Two 
children presented with meningitis and one with generalized seizures.  Case 7 
presented at the age of nine and eleven (pre-ART) with grand mal seizures, both 
secondary to severe electrolyte disturbances associated with gastroenteritis.  Case 
9 presented at the age of three years with meningococcal meningitis and case 8 
with an episode of viral meningitis at the age of twelve years.  Three children 
presented with ENT problems.  Case 4 presented with chronic ear infections, case 5 
with otorrhoea, and case 9 with otitis media.  All of the children‘s growth parameters 
were below the mean for their age.  Height and weight indices generally fell between 
the third and twenty fifth percentiles on standard growth charts with the exception of 
case 7 who presented with severe failure to thrive and wasting.  She was diagnosed 
with kwashiorkor (a severe form of protein-energy malnutrition) at the age of five.  
Case 3 was also diagnosed with marasmic kwashiorkor at the age of ten months. 
 
2.5.4.4 HIV Status 
All of the children had been perinatally exposed to HIV.  The date of diagnosis was 
obtained from the medical records of five of the nine children.  However, no record 
was found indicating the date of positive serology in the rest of the children (cases 1, 
4, 5 and 9).  The reason for this could be that the diagnoses were made at another 
hospital or that the records were lost.  Of those children in whom the diagnosis date 
was documented, three tested positive between one and three months old (cases 2, 
3 and 6).  The last two children were diagnosed at the age of eighteen months 














Table 5:  Profile of the children with regard to their HIV status. 
 
HIV Status 1 2 3 4 5 6 7 8 9 
CD4 Count:  Pre ART 699 505 411 319 328 538 180 286 432 
CD4 Count:  Post ART 821 715 1259 755 889 825 310 441 776 
Viral Load:  Pre ART _ _ _ 287000 _ 217000 _ _ 394000 
Viral Load:  Post ART LDL LDL LDL LDL LDL LDL LDL LDL LDL 
Hospitalisations:  Pre ART 5 8 4 0 3 16 8 4 9 
Hospitalisations:  Post ART 0 0 0 1 0 0 4 2 0 
ART: date started 15/3/03 6/3/03 26/2/03 4/4/03 14/2/03 6/3/03 22/12/03 14/2/03 14/02/03 





























Previous Regime _ _ _ AZT 
3TC 
NVP 







Adverse Reaction/s _ _ _ Abnormal liver 
functions NVP stopped 
_ Abnormal liver 
functions NVP Stopped 
_ Abnormal liver 













Table 5 describes the clinical profile of the children with regard to their HIV status.  The 
CD4 counts and viral loads pre ART were values ascertained at tests just prior to 
initiating treatment (within one month of initiation of treatment).  Values post ART, were 
values ascertained at tests done two years later (between May and August 2005). 
 
2.5.4.5 Indications for initiation of ART 
Seven of the children were started on ART because of recruitment onto a clinical trial.  
This was an open label multicentre trial to evaluate the pharmacokinetic efficacy and 
safety parameters of NVP, when administered in combination with AZT and 3TC for a 
period of forty eight weeks.  The children continued on this regime on cessation of the 
trial via continued funding by the pharmaceutical company.  The other two children 
were initiated on ART because of a clinical deterioration:  case 7 presented over a 
period of three months with persistent vomiting and diarrhoea (CMV Enteritis), wasting 
syndrome, severe electrolyte disturbances and pneumonia.  Her CD4 count at the time 
was 180.  Case 3 presented with failure to thrive, persistent fever, coughing and 
generalized lymphadenopathy.  Her CD4 count was 411.  She was started on ART at 
Red Cross Children‘s Hospital. 
 
2.5.4.6 Disease stage at initiation of ART 
Five of the nine children had CD4 counts below 500 (between 319 and 432).  One child 
(case 7) had a CD4 count below 200 (180).  Three of the children had CD4 counts 
above 500 (between 505 and 699).  The records do not indicate whether the children 
were formally clinically staged.  However, based on the clinical staging system of the 
World Health Organisation (WHO), one of the children qualified for WHO Clinical stage I 
(case 4) as she was asymptomatic.  Four of the children would have been classified as 
WHO clinical stage II (cases 1, 2, 3 and 6) and four subjects (cases 5, 7, 8 and 9) would 
have qualified for Clinical stage III.  Case 7 presented with an AIDS defining 
opportunistic infection, severe failure to thrive, and loss of developmental milestones 
(see Modified WHO Staging System, table 1).  Case 8 presented with severe failure to 
thrive coupled with clinical evidence of microcephaly.  Case 5 presented with a possible 
encephalopathy with an impression of deterioration in intellectual functioning and case 












motor slowing as well as neurocognitive problems and behavioural disturbances (see 
Table 5). 
 
Clinicians likewise did not document immunological staging.  Based on the Centre for 
Disease Control and Prevention (CDC) Classification system, seven of the children 
would have been classified as Category 2 (moderate suppression), one child Category 
1 (no suppression, case 4) and one Category 3 (severe suppression, case 7). 
 
2.5.4.7 Age at onset of ART 
Six of the children were between nine and eleven years old when ART was initiated.  
The rest were three (case 1), five (case 2) and six years old (case 3).  This represents 
an average time of eight years from birth to initiation of antiretroviral medications.  
 
2.5.4.8 Medication regimes 
The majority of the children were recruited into the research study so were initiated on 
triple therapy consisting of the NNRTI NVP, and two NRTI‘s AZT and 3TC.  Two 
children were started on medication at Red Cross Children‘s Hospital and were not 
subjects of the research study.  Case 7 was started, aged ten, on the NRTI‘s AZT and 
3TC and NNRTI Efavirenz.  Case 3 was initiated on two NRTI‘s 3TC and d4T, and the 
PI, KAL.  She was six years old at the time.  All treatment regimes (including those used 
in the research study) are based on standard protocols for first line treatments in HIV 
positive children. 
 
2.5.4.9 Side effects and tolerance 
There was a change of treatment regimen in three of the children, all due to the adverse 
effects of NVP.  Case 4 developed a skin rash within a month of starting the medication, 
necessitating an admission.  She was diagnosed with a grade 3 skin toxicity secondary 
to NVP, which was stopped and replaced with the PI, KAL.  Cases 6 and 8 both 
developed abnormal liver functions (three and six months post treatment initiation 
respectively) assessed to be secondary to NVP, which was replaced by KAL.  Except 
for the above, the medications were well tolerated with no further documented reports 
of side effects.  There were no direct links between behavioural manifestations and 














2.5.4.10  Response to ART 
There was a dramatic reduction in the number of admissions after initiation of ART, with 
the average number of admissions down from 5 to 0,6 per child.  Admissions were 
reduced to zero in five of the nine children.  The maximum number of admissions post 
initiation of ART were four (case 7), followed by two in case 8, and one in case 4.  Case 
7 presented with progressive disease despite ART.  She was re-admitted during the 
subsequent year for recurrent vomiting, persistently abnormal liver functions, 
gastroenteritis, PTB, and seizures secondary to metabolic disturbances.  Her last 
admission was in January 2005, after which her health steadily improved.  She was 
medically stable one year after initiation of the study.  Case 4 was the only child who 
remained well prior to starting ART, with no admissions until she had an adverse drug 
reaction.  She developed hepatitis in response to NVP.  She recovered fully after the 
medication was changed.  Case 8 was admitted (one year after starting ART) with an 
acute appendicitis and then a year later with viral meningitis.  There have been no 
admissions in any of the children since January 2005. 
 
The overall health status of the children has improved dramatically.  There has been a 
steady increase in weight but generally, ‗catch- up‘ growth in height has not occurred, 
with all of the children‘s growth parameters remaining between the third and twenty-fifth 
percentiles.  Despite the fact that baseline (pre-HAART) neurocognitive profiles were 
not done in the majority of children, a comparable improvement in overall intellectual 
functioning based on scholastic performance was not observed.  Similarly, there was a 
trend toward an increase in the rate of referrals for psychiatric evaluations subsequent 
to initiation of HAART.  Medical status of the children, one year after the study was that 
100% of the children remained virally suppressed (viral loads lower than detectible 
limits), and CD4 counts have increased in all of them.  There have been only modest 
increases in CD4 counts in two children (cases 7 and 8) with counts remaining below 
500 (CDC category II).  This represents an improvement from category III to II in case 
7.  Case 8‘s immunological staging has remained at Clinical Stage II.  The rest of the 














2.5.5 a summary of the clinical case series correlated with information extracted from 
the medical records. 
 
This group of PHIV children were initiated on HAART one year prior to referral for a 
neuropsychiatric assessment.  They presented with behavioural problems and poor or 
declining academic performance, in the context of significant improvements in their 
overall health status.  None of them was initiated on ART during infancy, with an 
average time of eight years from birth to initiation of treatment.  WHO clinical stages at 
initiation of ART were that one of the children was rated as Clinical Stage I, four were 
Stage II and four were Stage III.  Quantification of viral loads one year after the initial 
assessment revealed that 100% of the children were virally suppressed.  CD4 
percentages ranged between 28-45%. 
 
The outcome of the psychiatric assessment was that seven of the nine children were 
diagnosed with psychiatric disorders.  The majority (n=5) had diagnoses of ADHD, 
followed by mood disorders (n=2).  This outcome was similar to prevalence figures cited 
in the literature, which reports a prevalence of ADHD as high as 50% and a 30-40% 
prevalence of mood disorders.  Two children were diagnosed with psychiatric conditions 
that were possibly related to the direct effects of the virus on the brain, or due to the 
neurotoxic effects of ART: Delirium, and Mood disorder due to GMC.  One child was 
diagnosed with an Autistic Spectrum Disorder (PDD-NOS).  Responses to psychotropic 
medication were generally favourable with no severe adverse effects experienced.  
Therapeutic interventions consisted of parental guidance, behaviour modification, social 
skills groups, and individual counselling.  The underlying causes for or aetiology of the 
psychiatric presentations were possibly a combination of factors related to the HIV 
disease and ART, as well as, those due to psychosocial stressors experienced by the 
children at the time. 
 
CNS examination was normal in all but two of the children, who were noted to be 
microcephalic, with hyperreflexia in one of the two.  All the children underwent EEG 
examinations, which were abnormal in two of them.  Neuroimaging tests were normal in 
those referred for scans.  Lumbar punctures were performed in two children, in order to 
determine CSF viral loads, which were undetectable in both instances.  None of the 
children received diagnoses of HIV encephalopathy, which requires a triad of motor, 












motor deficits.  However, adult studies suggest that abnormal EEG‘s could be an early 
indication of HIV encephalopathy in otherwise neurologically asymptomatic HIV positive 
patients. 
 
The results of neurocognitive testing indicated that the majority of the children achieved 
IQ scores between borderline and moderate intellectual ability, with only two children 
functioning in the average range of intellectual ability.  It was not possible to determine 
whether the scores represented a decline in neurocognitive functioning, as most of the 
children were not previously tested.  However, in the three children previously tested, 
scores indicate a significant decline in two of the three.  The result of testing in the third 
child, who was previously diagnosed with PHE, showed an improvement in overall IQ 
score since last tested three years earlier.  
 
The children with the lowest neurocognitive scores (with the exception of one child) 
were the oldest (11-13 years).  These older children represent the group in whom there 
was the longest period before initiation of ART.  These older children did not, as a 
group, fare better on IQ testing, in contrast to early (pre-HAART) studies which suggest 
that older children may represent a group of ‗slow progresses‘, possibly infected by a 
less virulent strain of HIV (Koekkoek et al 2008, Thomaidis L et al 2010).  The older 
group (n=4) were all classified as WHO stage 3 and with the exception of one, tended 
to score in the lower IQ ranges.  The children with the three lowest IQ scores had the 
lowest pre-treatment CD4 counts and all were classified WHO stage III.  The child with 
the highest CD4 count and who was clinically classified WHO stage I, achieved a 
neurocognitive score in the average range and continues to attend a mainstream 
school.  Multiple aetiological factors contributed to the neurocognitive profile and poor 
academic performance, such as prenatal or perinatal insults to the brain, factors related 
to HIV (such as disease stage or degree of immune-compromise and baseline viral 
loads), presence of neurological deficits, possible executive functioning deficits, the 
impact of chronic illness and factors in the environment (such as a low caregiver-child 
ratio, inappropriate school placement, and a lack of remedial input). 
 
It was not possible to determine whether initiation of ART positively impacted on 
neurocognitive functioning, considering that the children were not routinely 
neurocognitively assessed pre and post treatment.  In spite of this, there was an 












persistence of academic problems and a trend towards placement in special schools in 
the years following initiation of ART.  Problems with memory, basic calculation, and 
concentration difficulties had been evident in follow-up sessions, suggestive of 
executive functioning deficits.  The results, therefore, could indicate that neurocognitive 
problems persist in perinatally infected children with late initiation of ART. 
 
Emerging from the clinical assessments, a number of questions were left unanswered: 
What is the impact of HAART on the neurocognitive functioning of children?  Do the 
neuropsychological deficits observed in HAART-naïve children persist on initiation of 
HAART?  Have the directly neurotoxic effects of some antiretroviral agents been 
explored in the paediatric population, and how may this impact on the neurocognitive 
functioning and behavioural profile of such a group?  What is the nature and prevalence 
of psychiatric presentations in PHIV children, and how does this differ from the general 
population?  To what extent are the psychiatric presentations virally or psychosocially 
related and what is the impact of HAART on the psychiatric morbidity of infected 
children?  In order to answer some of these questions, the literature was explored via a 
systematic literature review that explored the impact of HAART on the 
neurodevelopmental functioning of HIV infected children, the psychiatric manifestations 
of HIV in children and adolescents and possible treatment related effects on psychiatric 















This chapter reports on the findings of a systematic review of studies exploring the 
neurobehavioural presentations of youth receiving HAART.  This has important clinical 
implications as we attempt to define the psychopathology associated with HIV clearly, 
the long-term impact of the virus on neurocognitive functioning, and the potential for 
HAART to arrest or reverse neuropsychiatric sequelae. 
 
The first report documenting a positive response of progressive HIV encephalopathy to 
ART was published, over 20 years ago, in a study by Pizzo et al (Pizzo PA et al 1988).  
Subsequent studies demonstrated that continuous intravenous infusion of AZT 
monotherapy resulted in improved neurodevelopmental functioning in PHIV children 
(Brouwers P et al 1990).  By 2002, Mc Coig et al noted that combination therapies (dual 
therapies) were superior to monotherapy and that neurocognitive improvements were 
associated with decreased detectible CSF viral loads (Mc Coig C et al 2002). 
 
Research studies exploring psychosocial aspects of paediatric HIV have mainly focused 
on issues such as orphanhood, disclosure and adherence with very few studies and a 
limited body of literature exploring the nature and incidence of psychiatric disorders in 
PHIV children.  A review by Roa (Roa DR 2007) noted the limited literature related to 
psychiatric disorders.  Studies tended to report on symptoms rather than psychiatric 
syndromes.   
 
A few earlier studies (during the pre HAART era), which explored psychiatric 
presentations in younger children, do report high rates of anxiety, depression, and poor 
academic achievement (Bose S et al 1994, Mellins CA et al 2006).  In contrast, Mellins 
al failed to demonstrate an association between HIV illness, perinatal illicit drug 
exposure, and behaviour problems (Mellins CA et al 2003).  Similarly, Havens et al 
found no statistical difference in psychopathology between two groups of children (HIV 
exposed and non exposed), who were both exposed to perinatal illicit drugs (Havens JF 













In this review, I aimed to specifically explore the literature covering the psychopathology 
associated with HIV, in order to define the nature and prevalence of psychiatric 
disorders in children and adolescents receiving HAART.  A second aim is to establish 
the relationship between psychiatric presentations and neurocognitive, medical 
(disease stage, immune status and viral load) and CNS variables.  A further aim would 
be to identify studies exploring the possible neurotoxic side effects of antiretroviral 




A review of empirical studies examining the neurobehavioural status of vertically 
infected HIV positive children and adolescents on HAART was conducted: 
 
 Data bases used were PubMed and PsychINFO.  Search terms used were 
‗HIV‘, ‗child‘, ‗paediatric‘, ‗adolescent‘, ‗psychiatric, ‗behavioural‘, ‗psychotropic‘, 
‗antiretroviral‘, ‗HAART‘, neurocognitive, encephalopathy, ‗neurotoxic‘ and ‗side 
effects‘. 
 
 Relevant articles were searched for in reference sections of journal articles 
obtained. 
 
 Studies were reviewed and information documented in tables with the following 
headings: Author, Type of study, Sample, Methodology, Results, and 
Conclusions. 
 
3.2 INCLUSION AND EXCLUSION CRITERIA 
 
Criteria for studies to be included in the review, were for the children to be vertically 
infected and on HAART therapy, for them to have undergone a psychiatric and/or 
neurological assessment (including neuroimaging), and lastly, to have undergone 












published between 1997 and September 2011.  The rationale for limiting studies to 
those published during and after 1997 is that HAART became the standard of care after 
1997.  Studies where the majority of samples consisted of children not vertically 
infected (transfusion infected, via sexual transmission), or where ART was not 
specifically mentioned, were excluded.  The reason for this is that earlier studies using 
mixed samples of vertically and transfusion infected children consistently demonstrated 
differences in neurocognitive function between the two groups (ref).  Studies conducted 
after 1997, but in which treatment with HAART was not indicated, were excluded. 
 
3.3 RESULTS  
 
 3.3.1 Nature of studies:  
31 studies were identified, most of them conducted in the USA, the rest in the United 
Kingdom (UK1), Greece (1), Thailand (1), The Democratic Republic of the Congo 
(DRC, 1), the Netherlands (1), Brazil (1) and South Africa (2).  A number of USA studies 
were sub studies of large collaborative multi-site biomedical cohort studies, the 
Paediatric AIDS Clinical Trials group (PACTG studies 152, 219/219c, 338, 337 (Katz 
DG et al 2002), the Woman and Infant Transmission Study (WITS), (Diaz C et al 1998), 
and the Pediatric HIV/AIDS Cohort (PHACS) Study (Van Dyke R et al 2008).  Eighteen 
studies examined the neurocognitive status and the rest, behavioural and psychiatric 
presentations in children and adolescents.  Types of studies were retrospective record 
reviews (n=6), prospective studies (n=9), and 16 cross sectional studies.  Study periods 














Table 6: a quick reference to the research articles reviewed 
 
Author Type of study Sample size Aim/method Results Conclusions 




23 PHIV children on 
HAART.  Age range 
7months-10 years.  2 
groups: 1) 13 children on 
ABC, 3TC, ZDV 2) 10 
placebo/3TC/ZDV.  20 
children completed study. 
To test effectiveness of 
combination NRTI 
treatment on CSF viral load 
and clinical signs of 
encephalopathy.  Plasma 
and CSF viral loads and 
plasma CD4 counts 
performed.  CSF obtained 
at 8, 16 and 48 weeks.  
Merrill palmer Scale of 
mental tests (<35 months), 
WISC III for children 6 years 
and older.  Neuroimaging 
(CT) at baseline 
Significant CNS involvement, in 80% of total sample 
(46% group 1 and 70% group 2).  PHE diagnosed in 
61% group 1 and 80% group 2.  By week 48, 70% 
group 1 and 60% group 2 had normal neurological 
examinations.  No diagnoses of PHE at completion of 
study.  Decline in CSF HIV RNA in both groups 
(measurable viral loads decreased from 83% to 10% 
by 48 weeks).  Median levels decreased below 
detectible levels in both groups by week 8 and 16.  
All undetectable levels by week 48.  By week 48, 
emergence of different genotypic mutations in CSF 
and plasma, associated with viral resistance to ZDV, 
d4T and DDI.  Most common genotype to emerge 
was those resistant to 3TC.  42% IQ scores in average 
range at baseline.  Increased to 55% and 50% at 
week 48.   
Clinical improvements in 
neurological status as well as 
CSF viral loads are associated 
with ART.  Different genotypic 
mutations in CSF and plasma 
suggesting discordant viral 
evolution.  Agents with high 
CNS penetration should be 
included in regimens. 
Sanchez- 





58 of 189 children who 
developed progressive 
encephalopathy (PE).  2 
groups: 1 non ART (n10) 
and ART (HAART, mono-, 
To assess impact of ART on 
development of PE.  
Medical records reviewed 
of children who developed 
PE.  CD4 and CD8 counts 
Similar immune and virological markers in the 2 
groups.  Onset of medication average 1.22 years.  PE 
the first AIDS defining illness in 100% of group 1 vs. 
44% group 2.  Significantly higher mortality rates in 
children who developed PE (60% vs. 44%). 90% 
Dramatic decline in incidence 
of PE since 1997 and significant 
decline in deaths.  Starting ART 













dual therapy) before 
onset of PE (n27) 
documented.  Children 
followed up between 1994 
and 2000. 
deaths in group 1. 6.2x faster progression to PE in 
group 1, with median age of onset 0.6 years in group 
1 vs. 2.5 years in group 2.  Highest degree of clinical 
improvement in children on HAART (compared to no 
treatment, monotherapy or 2 agents).  Dramatic 
decline in incidence in PE after 1997 (5.6% 1997, 
0.0% 1998, 1.5% 1999 and 0.0% 2000) 
with slower progression to PE.  
Greatest neurological 
improvements were 
experienced in children on 
combination therapies.  ART 
therefore alters the natural 
history and neurological 
outcome of HIV. 




4 of 107 children met 
inclusion criteria.  Ages 
2.5, 4, 6.2 and 12.5 years.  
Children on PI based 
HAART regimens for at 
least 6 months. 
To identify children on PI 
based HAART who 
presented with 
neurocognitive decline.  
Records reviewed and 
results of physical 
examinations, 
neuroimaging, blood tests, 
and neurocognitive tests 
reviewed.  Tests: McCarthy 
Scales of Children’s 
Abilities, WISC III, CPRS,  
4 out of total of 107 experienced significant declines 
in neurocognitive scores 
1. 12.5yo female (F).  NFV, NVP, d4T.  Decline 
reversed when d4T replaced with ZDV and 
ABC added. 
2. 6yo male (M), Rit, d4T, DDI.  Significant 
decline PIQ (by 16 points) and VIQ (by 22 
points) at 18 months. 
3. 2.5yo M, Rit, Didanosine (ddI) and ZDV.  
ZDV stopped due to bone marrow 
suppression.  Global Neurocognitive Index 
(GCI) at 12 months was 24 points lower 
than baseline. 
4. 4yo M, NFV, NVP, and d4T.  GCI decreased 
by 17 points at 6 month follow up.  Decline 
in expressive language observed.  CNS 
examination revealed apraxia.  CT 
Despite clinical and immune 
stability, some children do 
experience neurocognitive 
decline.  Viral control not as 
effective in the CNS.  May be 
due to poor penetrance of 












revealed mild cortical atrophy. 
Gaughan DM 





1808 PHIV children < 15 
years.  Controls 1021 
PHEU siblings. 
To establish incidence of 
psychiatric hospitalisations 
in PHIV children.  PACTG 
database explored to 
determine psychiatric 
hospitalisations between 
Sept 2000 and Dec 2002.  
Psychiatric hospitalisation 
and diagnoses, compared 
to hospitalisation rates in 
HIV - children 
25 PHIV children hospitalised.  Increased to 32 when 
age limit disregarded.  Age at first admission 11 
years.  Significantly higher rates of psychiatric 
hospitalisations compared to population norms 
(6.17 cases per 1000).  Majority depression, 
behavioural disorders, suicide attempts, or ideation.  




PHIV children are at increased 
risk of psychiatric 
hospitalisation and at high risk 
of depression and suicide. 
Chiriboga C 





Mean age at baseline 23 
months.  11 older than 3 
years.   
Determine impact of 
HAART on CNS status, rates 
of PHE and clinical 
outcomes.  
During 2000, neurological 
assessments performed, at 
baseline and 6 months.  
ADHD diagnosis made 
using DSM IV criteria.  
Tests: WISC III, BSID and 
Mc Carthy Scales of Infant 
Development 
Rate of PHE 1.6% (n=2) in  
Cumulative prevalence arrested PHE 10% (n=13). 
62% still had abnormal CNS assessments. 
12 of 13 presented with developmental delay.  8 
improved at follow up (after treatment).  
Significantly higher rates school placement in special 
education in children previously diagnosed with 
PHE. 
28% diagnosed ADHD.  ADHD diagnosis not 
significantly related to baseline VL, CD4, or CD8 
percentages.   
Marked decline incidence PHE 
demonstrated.  May relapse if 
poor virological control, 
highest risk in arrested PHE.  
PHE diagnosis predicted by 
high viral load (VL).  Despite 
improvements, high rates 
residual neurological, 
neurocognitive, scholastic 



















Age range 4 months – 17 
years.  Previously treated 
with ART but never with 
PIs 
To assess impact of HAART 
on neuropsychological 
status and PHE and 
determine correlation with 
viral load. 






WISC III, Stanford Binet.  
Tested at base line then 
per specified schedule over 
48 weeks. 
Baseline: neuropsychological scores significantly 
poorer compared to population norms.  Mean 
neurocognitive and short term memory score 1 SD < 
norm.  Mean IQ 83.5.  13% scores above mean of 
100.  16% scores 2SDs below norm.  CNS 
examination abnormal in 13%.  Poorer 
neuropsychological performance associated with 
higher baseline VL.  Neuropsychological 
performance not superior in those who achieved 
LDL.  Post treatment with PI: No significant positive 
neuropsychological effect after 48 weeks of 
treatment.   
Poorer neuropsychological 
functioning in PHIV children.  
Higher baseline VL predicts 
poorer cog functioning.  Impact 
of PI therapy minimal, despite 






146 PHIV children born 
between 1990 and 2003 
To assess long-term impact 
of ART on neurocognitive 
function and PHE.  Data 
collected during two times: 
Pre and post HAART.  
Examined for 
Improvements in 
neurocognitive status.   
Significant decline in diagnosis of PHE.  Mean scores 
for all below norm of 100.Significant increase in 
neurocognitive scores between 2 times.  All 
improved IQ scores of average 4.9 points.  Higher 
caregiver child ratios and home environment 
associated with higher IQ.  Lower VL and higher CD4 
weakly associated with increase in IQ scores.  No 
association CSF penetrating drugs and IQ scores. 
Declines in prevalence of PHE 
and improvements in 
neurocognitive status since use 
HAART.  Significant numbers 
still present with 
neurocognitive delays.  May 
represent discordant patterns 
of viral resistance in plasma 
and CNS.CD4 and VL weakly 


















62 PHIV children, 2 
categories according to 
disease severity.  Mild 
disease (CDC category N, 




outcomes of children 
younger than 3 years.  
Tests: Griffiths 
developmental test, BSID 
for infants, Mc Carthy 
Scales preschoolers. 
50% severe disease (CDC category C).  PHE in 22.5%.  
Significantly more CNS abnormality, lower CD4 
count in CDC Category C. Similar VL responses.  
Infant assessment: Lower MDI and PDI scores 
compared to norms on Griffiths and BSID.  Poorer 
expressive verbal scores.  Group C scores lowest in 
all categories.  Preschool assessment: Entire cohort 
lowers motor mean scores.  Scores group C 
significantly lower than group A/B for perceptual-
performance scores 
Significant risk of neurological 
and developmental deficits in 
children presenting with severe 
disease at diagnosis.  Trend is 
toward persistence despite 
immune reconstitution.  
 
Martin P et al 
2006 
Cross sectional 41 
Mean age 11.2 years. 
Assess medical indices, 
neurocognitive function, 
and neuroimaging after 1 
year on HAART.  
Neuroimaging done.  WISC 
III administered. 
  
Mean CD4 608,3.  Mean CD4% 22.  Mean VL 100 588.  
LVL in 17.  Mean IQ and PSI (processing speed index) 
average range.  However, most low average to 
borderline.  Arithmetic scores significantly lower.  
Ventricular enlargement and subarachnoid 
dilatation commoner than white matter 
abnormalities and calcification. 
CNS disease risk remains 
despite HAART.  Those with 
brain scan abnormalities 
perform significantly more 
poorly.  CD4 < 500, lower 
scores on processing speed.  VL 
seems unrelated to 
neurocognitive scores.   
Mellins C et 
al 2006 
Cross sectional 47 
32 on ART 
Establish rate and type of 
DSM IV disorders 
Instruments: DISC IV, CBCL 
CDI.  BDI and STAI to 
evaluate parents. 
 
51% CD4 >500, 9%  < 200.  55% psychiatric diagnosis 
of which 26% multiple diagnoses.  Most common 
Anxiety, Disruptive Behaviour Disorders, Mood 
Disorders.  Caregiver depression associated with 
CBCL problems.  No association between CDI and 
caregiver mental health.  Caregiver anxiety 
High rates of psychiatric 
disorders, higher than 
population norms, comparable 
to high risk groups (ethnic 













significantly associated with CBCL problems.  
New MJ et al 
2006 
Cross sectional 57 PHIV children aged 6-
12 years. 
Prevalence of mental 
health problems (MHPs) 
and psychological 
adjustment in caregivers 
and children.  
Instruments: BSI (parents), 
(C-DISC 4, SCID, SSPQ, 
CBCL, WISC III). 
Caregiver: 13 out of 57 had a psychiatric disorder.  
37% HIV+.  Child: 21% using psychotropic medication 
14% previous or current Diagnosis of ADHD, 12% 
mood disorder, 5% both, 2% ‘other’ (anxiety, 
enuresis) 
 
Despite reports of MHPs and 
psychotropic use, only small 
proportion met criteria for 
DSM IV diagnoses.  May 
indicate resilience on the part 
of PHIV children or that 
caregiver information less 
reliable. 
 
Nozyce M et 
al 2006 
Cross sectional 298, mean age 7.2 yrs Neurocognitive, 
behavioural and 
neuroimaging in clinically 
stable children on ART. 
Baseline CT/MRI.  
Test used WISC III 
Mean FSIQ 86, significantly < population norms. 
52% =behavioural problems.  Neuroimaging: 7% 
basal ganglia or subcortical calcifications, 3% mild 
cortical atrophy, 1% white matter abnormalities, 1% 
focal mass lesion.  No associated behaviour 
problems and CT/MRI findings 
 
HIV+ children have a   4X 
increase rate of behavioural 
problems, lower 
neurocognitive scores than 
general pop.  Higher rates 
behaviour problems than other 
chronically ill children.  Lack of 
gender differences in ADHD 
symptoms may indicate HIV 
effect on brain.  No link with 
illness severity.  Aetiology 
likely multifactorial. 




64, mean age 15.3 years 
94% on HAART 
Document DSM IV 
diagnoses, psychotropic 
 45% prescribed medications:  Anti -depressants 
30%, stimulants 25%, atypicals 16%, and anxiolytics 
Higher rates of psychotropic 












review drug use.  Establish link 
with medication use, loss 
of a parent 
3%.  Loss of biological parent associated with 
psychotropic med prescription.  Psych diagnosis: 
44% formal Diagnosis (90% on meds), Depression 10, 
ADHD 7, ADHD and depression 5, ADHD and mood 
1, ADHD and psychosis 1, ADHD and Asperger’s 1, 
psychosis 1, Anxiety 1, PD 1. 
illness, similar to referred 
population.  Depression 
important clinical issue in older 
children.  May be related to 
high no stressors, genetic or 
immune status.   






Explore emotional and 
behavioural problems in 
Zambian adolescents, link 
with disclosure.  Semi 
structured interviews.  
Instruments: SDQ, Parent 
and Youth Version.  
 
58.3% not HIV aware, 73.2% on ART 
WHO staging: Stage 1(21%), 2 (39.4%), 3 (28.3%), 4 
(5.5%).  Compared with UK youth, Zambian youth 
(ZY) 2X likely to score outside normal range for total 
difficulties, 3X more likely to have extreme scores 
for emotional symptoms, 7X more likely abnormal 
scores for peer problems.  Comparable rates of 
conduct disorder.  Hyperactivity rates less than half 
in ZY .No relation WHO staging.  No differences HIV 
aware, unaware.23/38 in favour of support group 
High rates of emotional, peer 
group problems in HIV+ 
Zambian youth.  Outcomes not 
related to health status or loss 
of a parent.  Knowledge of HIV 
does not negatively impact on 
mental health.  Disclosure may 
promote adherence and 
facilitate access to 
psychological support 












 HAART regimen, over 
96 weeks.  All received 
Stav, RTV, NVP 
Bloods at baseline and 
periodically.  CT at 
Median CD4 589, VL 3.9 log copies/ml. 
2 had CNS disease at baseline.  Median FSIQ 96.5 at 
baseline and remained same at 24, 48, 96 weeks.  
VIQ significantly lower than PIQ all times. 
1had a decline in scores at 24 weeks (improved after 
ZDV added).  5 improvements to week 48.CNS 
disease in 3.  All decrease in VL.  10 LDL by week 48.  
Maintained by 8 to week 96.  Mean increase CD4 of 
Most neurocognitively stable 
after initiation HAART, minimal 
CT brain abnormalities 
suggesting a neuroprotective 












baseline, weeks 24, 48, and 
96.  Test: WISC III. 
225 by week 48 and 307 week 96. 




1204 PHIV and PHEU 
children. 
3 cohorts; 1 (born 
between 1992 and 1997, 
n 275).  2 (born after June 
1997 n 929,  
3 HIV+ children, n91 (1 or 
more BII assessment 
before started PI 
Impacts of HIV on 
neurodevelopment before 
and after initiation of 
HAART containing PI. 
Method: BSID 1
st
 (BI) and 
second (BII) ed. Assessed 
at entry, 6 monthly till 2-3 
years. 
Cohort 1: Baseline (< 1 year): mean Mental (M) and 
Psychomotor (P) scores 105 and 107 in PHEU 
PHIV: mean M and P scores 85 and 77.  More PHIV 
floor scores of <49.  Higher P scores whose mothers 
initiated on ART during pregnancy.  Significantly 
lower M and P scores at 6-24 mo in PHIV.  Lower 
mean M and P scores if CD4 < 25%.  Decline in M and 
P scores with increasing age, regardless of HIV status 
Cohort 2:PHEU: mean M and P 92 and 90.PHIV: 85 
and 83.Scores for both significantly < norm.  Higher 
% of floor scores in PHIV, no significant difference by 
maternal ART or drug use.  No correlation CD4%, 
disease category, and M and P scores. 
Follow up 2 and 3 yrs: Trend for M and P scores to 
decline at greater rate in PHEU and for PHIV to 
improve relative to PHEU over time.  Higher % PHIV 
with significant delays (<70), difference smaller over 
time.  Greater % PHEU with significant delays with 
increasing age.  Cohort 3: Significantly decreased 
rates of decline after started PI  
HAART has a positive but 
limited impact on 
neurodevelopment.  Children 
with more severe immune 
suppression are at greater risk 
of neuro-developmental 
deficits, which may predict 
survival.  Initial difference in 
neurocognitive scores 
diminished with age, decline in 
scores in PHEU children 
highlights impact of other 
psychosocial factors, which 
negatively affect neuro- 
neurocognitive development.   
Koekoek S et 
al 2008 




Mean CD4=30 and LDL at 6 months of HAART.  Mean 
IQ 95.  Scores did not significantly deviate from 
Gross neurocognitive deficits 












 impairments in school 
going children.  Define risk 
and protective factors for 
neurocognitive 
functioning.  Tests: R-SON, 
ANT Programme 
 
norm.  Five children scored 85 or lower, 9 between 
85-100, 8 above 100.  Neuropsychological tests: 
Significantly lower scores compared to norm in 4 out 
of 7 tests (verbal fluency, baseline speed, and 
pattern recognition, shift set.  Poorer visuospatial 
tasks.  Pursuit, tracking, tapping =norm).  Mean 
reaction time associated with longer duration of 
treatment.  Higher CD4 baseline associated with 
higher accuracy in pattern recognition. 
children.  Evidence of more 
subtle and specific executive 
functioning deficits.  Specific 
neuropsychological tests are 
more sensitive than global 
measures PHIV children on 
HAART.  Indices of processing 
speed particularly sensitive to 
detecting neurocognitive 
deficits. 






39 ambulant children, 14 
of them.  6 yrs. and older 
Lam, Eva, Rit 
Impact of HAART on 
neurocognitive 
functioning, pre and post 
ART, over 6 months 
Assessed pre and 6mo post 
onset HAART.  Tests: 
Griffiths, TROG, Ravens, 
DAP.   
56% CDC category C. Significant improvement CD4, 
VL, and nutritional status after HAART onset.  CNS 
examination abnormalities: 13 baselines, 11 follow 
up.  Neurocognitive functioning:  Most scores low 
average to borderline, No significant differences pre 
and post initiation of HAART.  Language and visual 
perception deficits evident. 
Highly prevalent CNS and 
neurocognitive deficits, remain 
static after 6 months on 
HAART.  Language 
development greatest deficit, a 
predictor of long-term 
educational outcome.  
Recommend initiation of 
HAART in infancy, referral to 
early intervention programmes 
Brackis–Cott 
E et al 2009 
Cross sectional  340 (206 HIV+) 
9-16 yrs 
To describe school 
functioning, word 
recognition, and receptive 
language ability of older 
PHIV children achieved significantly lower scores 
than PHEU children.  37% PHIV children attended 
special education vs. 28% PHEU.  Mean CD4 602, VL 
3150 copies/ml. HIV status significantly associated 
Older HIV infected and affected 
children present with poor 
language skills.  Educational 












PHIV children compared to 
HIV – peers.  Tests: PPVT 
III, WRAT-3. 
with test scores. if left unattended, will later on 
impact on health literacy. 
Chernoff M 
et al 2009 
Prospective 
study 
575 (319 PHIV, 256 HNU 
controls) 
Compare and describe 
behavioural interventions, 
psychotropic drug 
treatment patterns in PHIV 
and PHEU children.  
Instruments: CASI-4R, CI, 
and YSI. 
 
Similar prevalence psychiatric symptom (61% each 
group one psychiatric condition).  Degrees of 
impairment similar.  More conduct problems in 
PHEU group.  PHIV children more likely to have 
received interventions, psychotropic medication.  
Medications prescribed: Methylphenidate (n59), 
amphetamine salts (32), Atomoxetine (13), 
Risperidone (13), Sertraline (12), Fluoxetine (12), 
and Bupropion (6).  Stimulants prescribed across all 
age groups, SSRIs mostly adolescence. 
PHIV positive and negative 
youth present with similar 
symptomatology and 
impairment.  However, more 
PHIV children receive 
interventions for emotional 
and behavioural problems, 
higher lifetime rates of 
psychotropic medication use.  
This may reflect better access 
to healthcare systems for PHIV 
youth.   
Mellins CA et 
al 2009 
Cross sectional 206 PHIV, 134 PHEU 
youth aged 9-16 years. 
To examine prevalence, 
type of psychiatric and 
substance use disorders.  
Examine the association 
between HIV and mental 
health outcomes.  
Instrument: DISC-IV. 
High rates of psychiatric disorder in both groups, but 
significantly higher rates in the PHIV group.  
Commonest diagnoses Anxiety disorders.  ADHD 
more prevalent in PHIV group with 2x greater 
likelihood compared to PHEU youth.  PHIV youth 
significantly more likely to have seen a therapist for 
emotional and behavioural difficulties.   
This study demonstrates an 
association between perinatal 
HIV infection and youth 
psychiatric outcomes.  High 
rates of psychiatric disorders 
are evident in PHIV and PHEU 
youth.  HIV treatment 
programmes should include 












prevent long-term negative 
outcomes. 
Mellins CA et 
al 2009 
Cross sectional 340 (206 PHIV, 134 PHEU 
adolescents, aged 9-16 
years.  Mean age 12.6 
years. 
To explore link between 
sexual and drug behaviour 
and youth mental health.  
Explore impact of caregiver 
mental health and family 
functioning on MHPs and 
risk behaviours.  
Instruments used: DISC- IV, 
CDI, STAI (child version), 
BDI and STAI, PCRI  
Most prevalent substance was alcohol in both 
groups, followed by cannabis, and cigarettes.  3% 
diagnosis Substance Use Disorder (SUD).  58% not 
sexually active.  Unprotected sex reported in 33% 
(40% PHIV and 26% PHEU youth).  No direct 
association of caregiver mental health or family 
functioning with youth substance abuse.  There was 
an indirect effect of caregiver psychiatric symptoms 
on youth substance use via youth mental health 
symptoms.  No association between HIV status and 
psychiatric symptoms or risk behaviour.   
PHIV and PHEU youth are 
engaging in sexual behaviours 
and substance use with high 
rates of unprotected sex 
reported.  Caregiver and youth 
mental health may play critical 
roles in influencing risk 
behaviours.  Highlights need 
for integrated mental health 
services, risk reduction 
strategies that could be 
incorporated into existing 
mental health programmes.   
Puthanakit T 
et al 2009 
Prospective 
study 
122 children aged 6-12 
years.  PHIV (n 40), PHEU 
(n 40) and HNU (n 42) 
To evaluate neurocognitive 
functioning in school 
children pre and post 
HAART initiation (6 months 
and 30 months).  Test: 
WISC-III. 
 
 Mean FSIQ =79 PHIV vs. 88 PHEU vs. 96 HNU 
controls.  Post treatment: PIQ remained same in all 
groups, VIQ significantly decreased in all 3 groups.  
21% PHIV vs. 49% PHEU vs. 76% HNU controls had IQ 
scores in average range.  More infected children 
scored in the neurocognitively handicapped range.  
HIV infection was significantly associated with poor 
neurocognitive performance.  20% of infected 
children were in lower than age appropriate grades. 
Poorer neurocognitive 
functioning in PHIV children 
than age matched PHEU and 
HNU children.  Long-term ART 
does not result in improvement 
in neurocognitive functioning 
despite virological control, 
immune reconstitution.  Early 












irreversible.  Early initiation of 
ART should be a consideration 
to preserve neurocognitive 
functioning.   
Van Loon SE 
et al 2009 
Cross sectional 81 PHIV children aged 6-
16 years.  Mean age 9.8 
years.  86 HIV- children 
(siblings or children from 
community). 
To compare neurocognitive 
functioning of HIV+ and 
HIV- children.  Examine 
effect of stage of disease, 
CD4%, medication, and 
child-to-adult ration on 
neurocognitive 
functioning.  Test: RCM 
PHIV children achieved lower mean scores on RCM 
than PHEU children even after controlling for 
differences in age.  No significant correlation 
between neurocognitive functioning, stage of 
disease and CD% percentages.  No association 
between neurocognitive functioning and specific 
ART regimens.  No significant differences related to’ 
child- to- adult ratio’.   
PHIV children perform more 
poorly in tests of 
neurocognitive functioning 
regardless of stage of disease, 
immune status, and type of 
medication or child to adult 
ratio.   




158 (35 PHIV, 35 PHEU, 90 
HNU controls).  Age range 
18-71 months.  All HAART 
naïve and initiated on 
d4T, 3TC and NVP 
(children> 15kg) and AZT, 
Lam and NVP if < 15kg 
Impact of HAART on 
neurocognitive 
functioning, pre, and post 
initiation of HAART.  Tests 
used: BSID, SON, PDMS. 
Mean scores lowest in PHIV (65.8), intermediate for 
PHEU (74.8) and highest for controls (84.6) at 
baseline.  Improvement in scores in all 3 groups 
after 1 year, statistically significant for motor but 
not neurocognitive scores (84.3 vs. 87.6 vs. 96.5).  
Mean scores PHIV children similar to PHEU but 
lower than controls, after 1 year.  Increases in 
neurocognitive scores higher among children 
presenting early (in disease process) for treatment.  
There was an age related acceleration of IQ scores, 
with accelerated neurocognitive and motor scores 
observed in younger children (aged < 29 months) 
Neurocognitive and motor 
development of PHIV poorer 
than PHEU children and 
healthy controls prior to 
initiation of HAART.  
Improvements in neuro -
development evident in PHIV 
children but only substantial in 
motor domains.  
Neurocognitive improvements 
remain restricted, as PHIV 












neurocognitive scores as 
controls, after 1 year of HAART.  
Greatest gains achieved in 
children who present for 
treatment early in the course 
of the disease process. 




81 PHIV children, median 
age 15 years.  Median age 
treatment initiation 3 
years. 
To examine relationship 
between severity of HIV 
disease, psychiatric and 
neuro- cognitive outcomes. 
3 monthly follow ups, 
annual neuropsychiatric 
testing using WISC-IV, 
WASI.  Psychiatric 
diagnoses via clinical 
assessments. 
48% (n39) had psychiatric diagnosis, 18.5% (n15) had 
multiple comorbidities.  Mood disorders most 
prevalent (30.8%), the ADHD (18%), psychotic 
disorder (8.6%), non-ADHD behavioural disorders 
(13.6%), eating disorders (2.5%). 16% ever 
hospitalised for psychiatric illness and 32% ever 
prescribed psychotropic medication.  Mean FSIQ 
=87.  Learning disability (LD) diagnosed in 42%.  
35.8% received specialized learning support.  
Lifetime diagnosis PHE 17%.  Significant association 
between lifetime history of psychiatric diagnosis and 
more severe disease (Class C diagnosis).  Significant 
association between lower FSIQ, presence of a LD, 
specialized learning support and Class C diagnosis.  
No significant differences in FSIQ between patients 
initiated on HAART before or after AIDS diagnosis.   
High rates of psychiatric illness, 
hospitalisation, and learning 
difficulties experienced by 
PHIV adolescents.  There is an 
increased risk of psychiatric 
and neuro- cognitive 
impairment in perinatally 
infected adolescents with a 
distant history of an AIDS 
diagnosis.  Results support 
early initiation of HAART 
during infancy or before AIDS 
diagnosis. 
Thomaidis I 
et al 2010 
Matched case 
control study 
20 PHIV children.  Age 
range 3-18 years.  Mean 
To assess impact of HAART 
on neurocognitive 
75% (n 15) no neuroimaging abnormalities (NAs) 
(group 1), 5 NAs (group 2).  Of those 3/5 had 
Greater risk of neurocognitive 












age 11.76 years. functioning compared to 
normal controls.  Establish 
association of social 
/emotional problems with 
neuroimaging 
abnormalities.  SDQ, WISC 
III, and Griffiths.  CT or 
MRI, neurological 
examinations. 
abnormal neurological examinations.  Age of 
initiation of HAART or duration of treatment did not 
differ between 2 groups.  Higher neurocognitive 
scores in group 1 compared to controls:  40% 
average, 20% mild, 40% moderate vs. PHIV:0% 
average vs. 20% mild, 40% moderate, 40% severe.  
Majority normal SDQ scores in group 1, abnormal 
social, and hyperactivity scores.  Peer relationship 
problems in group 2.  
 
presenting with neuroimaging 
abnormalities.  Patients 
without neuroimaging 
abnormalities are more likely 
to suffer maladjustment in 
emotional and activity spheres 
as opposed to those with 
neuroimaging abnormalities, 
who may present with 
compromised social skills. 
Gadow K et 
al 2010 
Cross sectional 323 PHIV, 259 HIV- 
controls  (HNU living with 
HIV+ person or HNEU 
children). 
Age range 6-17 years old. 
To compare rates of PHIV 
and HIV- peers.  
Instruments: CASI, ASI, YSI, 
SAFQ, subscales of the 




Higher rates of psychopathology in both groups 
compared to population norms.  Most common in 
both groups was ADHD, similar rates in older group 
(11 HIV+, 12% controls) but higher rates in younger 
group (17.05 vs. 12.6%).  Higher rates of 
somatisation in PHIV group and higher rates of 
aggressive and antisocial behaviour in control group.  
Lower rates mood disorders in HIV+ group.  Higher 
rates of interventions for academic and psychiatric 
problems in PHIV group.  Higher rates severe 
oppositional and defiant behaviour, separation 
anxiety, and negative life events reported in HIV 
aware group.   
 PHIV group lower scores for processing speed.   
Both PHIV and community 
based peers at high risk of 
psychopathology, with no 
differences in overall rates of 
psychiatric problems.  HIV 
negative peers are at greater 
risk of disruptive behaviour 
disorders, which may reflect 
greater access to interventions 
by PHIV youth.  Higher rates of 
psychiatric interventions are 
evident in the PHIV group, 
which may suggest that 












problems are higher than these 
results suggest. 




49 PHIV adolescents aged 
10-19 years.  Mean age 
12.5 years.  All onset 
HAART after AIDS 
diagnosis. 
To examine long-term 
outcome of HIV illness, 
psychological and school 
function.  Instruments: 
QOLA (5 domains of 
psychological, physical, 
social/school functioning, 
health perception, HIV 
symptoms). 
89.8% attended school.  HIV status disclosed to staff 
in only 38.6%.  School failure and dropout reported 
in 51% and 28.6% respectively.  36.7% felt 
discriminated against because of HIV status.  High 
score achieved in all 5 domains, highest for physical 
functioning and lowest for social/school functioning.   
Disclosure rates are low 
despite reaching adolescence.  
School failure and dropout 
rates are high.  Improvements 
in HIV disclosure and early 
detection of school problems 
need to be a focus at clinic 
visits, as part of long-term 
follow up. 
Malee K et al 
2011 
Cross sectional 295 PHIV, 121 PHEU 
children.  Age range 7-16 
years. 
To establish impact of HIV 
infection by comparing 
PHIV children and PHEU 
children.  To identify risk 
factors associated with 
mental health problems 
(MHP’s).  Instruments 
used: BASC-2, BASC-2 Self-
Report of Personality 
(SRP), BASC-2 PRS.  Two 
rating indices, the BSI) and 
ESI.  Caregiver functioning: 
CDQ, WASI, PCR.   
Higher rates of MHPs in both groups compared to 
US population.  Higher prevalence of MHPs among 
PHEU than PHIV children (38% vs. 25%).  BSI scores 
in ‘at risk’ or clinically significant range for 29% 
PHEU and 19% PHIV youth.  ESI scores in ‘at risk’ or 
clinically significant range in 17% PHEU vs. 12% PHIV 
group.  Lower child IQ, younger age, caregiver 
psychiatric disorder, caregiver functional limitations, 
caregiver limit setting problems, associated with a 
higher odds ratio of MHPs. Stronger association 
between caregiver psychiatric status and youth 
MHPs for youth living with biological mothers. 
HIV exposed children 
regardless of infection are at 
increased risk of MHPs. 
Environmental risk factors such 
as caregiver psychiatric 
disorder are particularly 
associated with child MHPs. 
Higher rates of MHPs in PHEU 
youth may reflect less access to 
comprehensive medical and 
psychological care, than PHIV 

















54 PHIV youth, mean age 
15 years and aware of HIV 
diagnosis, 165 age 
matched PHEU children 
Compare risk of depression 
among PHIV adolescents   
and matched controls.  CDI 
Children’s depression 
Inventory (Thai version) 
administered to all 
participants. 
39.3% of all participants had a positive CDI score (15 
and more).  Mean score significantly lower among 
PHIV youth (27.8%) compared to controls (43%).  No 
significant difference between groups in terms of 
suicidal thoughts, plans or attempted suicide.  
Positive correlation between positive CDI scores, 
planned or attempted suicide and reports of sexual 
intercourse. 
Significantly decreased rates of 
possible depression were 
found among PHIV youth 
compared to school-based age 




SDQ:     Strengths and difficulties questionnaire, Griffiths: Griffiths Developmental Scales, TROG: Test of Reception and Grammar, Ravens: Ravens Progressive Coloured Matrices, DAP: Harris-
Goodenough Draw a Person Test, SON: Revised Snijders Oomen Non- verbal intelligence Test, ANT Amsterdam neuropsychological Tasks Programme, PDMT: Peabody Developmental and 
Motor Test, CASI-4R): Child and Adolescent Symptom Inventory, CI: Child Inventory, YSI: Youth Self Report Inventory, PPVT III: Peabody picture Vocabulary Test , WRAT-3:  Wide Range 
Achievement Test , PCRI: Parent Child relationship Inventory, WASI: Wechsler Abbreviated Scale of Intelligence, ASI: The Adolescent Symptom inventory, YSI :Youth (self report) Inventory, 
SAFQ: Social and Academic Functioning Questionnaire, CDI: Children’s depression Inventory, QOLA: Quality of Life Assessment, BASC-2: The Behavior Assessment System for Children-2
nd
 
edition,  BASC-2 SRP: BASC-2 Self-Report of Personality (SRP), BASC-2 PRS:  BASC-2 Parent Rating Scale (PRS), BSI: Behavioural Symptoms Index, ESI: Emotional Symptoms Index (ESI).CDQ: 












The majority of study subjects were from ethnic minorities and of low socioeconomic 
status (SES).  Most studies did not indicate whether study subjects were exposed to 
illicit drugs prenatally.  Sample sizes ranged from 17 to 1204.  The age range was 
between infancy (<1 year) to 19 years and there was an equal male female ratio.  
Comparison groups were perinatally HIV exposed but uninfected (PHEU) or HIV 
negative, HIV unexposed (HNU) children.  Population norms or published statistics 
of clinical samples such as psychiatrically uninfected youth were compared to the 
study samples.  Disease stages ranged from asymptomatic (CDC category N) to 
severely ill (CDC category C). 
 3.3.2 Measures 
1)  A number of studies undertook serial blood and CSF samples.  CD4 levels 
were measured in order to evaluate the response to treatment.  CSF and 
plasma viral loads were measured, both to assess treatment effects and to 
establish whether there was a differential impact of the medication on 
plasma levels compared to CSF levels of the virus.  Genotype analysis of 
blood and CSF was conducted to measure the emergence of mutations 
associated with viral resistance to treatment.  
2) Neurological examinations were conducted to establish the presence of 
neurological deficits, particularly progressive encephalopathy.  
3) Neuroimaging tests such as CT and MRI brain scans were conducted and 
severity ratings ascribed and matched with medical variables and 
neurocognitive scores. 
4) Neurocognitive tests were conducted.  The following tests were commonly    
used: 
a) The Wechsler Intelligence Scale for preschool and primary school 
children older than 6 years was used.  The Wechsler Intelligence Scale 
for Children-Revised (WISC-R) or the 3rd edition (WISC III (Kaufman AS 
1998).  Scores of the Full Scale IQ (FSIQ), Performance IQ (PIQ), and 
Verbal IQ (VIQ) were examined, as well as, the Processing Speed and 













b) McCarthy Scales of Children‘s Abilities were administered (Bradley-
Johnson S 2001). 
c) The first and second edition of the Bayley Scale of Infant Development 
(BSID), were administered (Lee LLS et al 2005, Bradley-Johnson S 
2001).  
d) The Stanford Binet Intelligence Scale was used to test short term 
memory and vocabulary (Becker KA 2003). 
e) Neuropsychological testing was conducted.  The subtests of the WISC III 
were used to assess language, memory, attention, visuomotor and visual 
spatial processing, academic measures, and motor performance.  
Subtests used were Digit Span, Arithmetic, Digits Backward, Picture 
Completion, Picture Arrangement, Block Design, and Coding.  Executive 
functions such as Sequencing and Planning, Attention to Detail, and 
Visual Spatial Organization were tested. 
f) The Griffiths neurodevelopmental test for infants and preschoolers was 
used (Aylward GP 1997, Lee LLS 2005). 
 
5) Psychiatric evaluations were conducted by using clinical interviews and well 
validated diagnostic scales.  The following rating scales and checklists were 
commonly used to assess the children:  The Child Behaviour Checklist 
(CBCL) (Achenbach TM et al 2000), the Childhood Depression Inventory 
(CDI) (Kovacs M 1982), the Diagnostic Interview Schedule for Children 
(DISC IV) (Schaffer D et al 2000), the State Trait Anxiety Scale (Marteau TM 
et al 1992).  Parental psychopathology was assessed by means of The Beck 
Depression Inventory (BDI) (Beck AT et al 1961), State Trait Anxiety 
Inventory (STAI), the Screen Patient Questionnaire (SSPQ), and the Clinical 
Diagnostic Questionnaire (CDQ), which also assessed maternal Post 
Traumatic Stress Disorder (PTSD) and substance abuse (Blake DD et al 













Table 7: A list of rating scales and checklists most commonly used. 




Children (DISC IV) 
Highly structured 
diagnostic instrument to 
detect common DSM IV 
diagnoses.  Lay 
interviewers require 




113 item scale (completed by parents), 
which assesses behavioural and 
emotional functioning in children aged 
4 to 18 years.  Standardized scores 
obtained for internalizing and 
externalizing behaviour. 
  Childhood 
Depression 
Inventory (CDI) 
For children aged 7-19 years.  Assesses 
for symptoms of depression. 
  *Beck Depression 
Inventory (BDI) 
21 items to assess depressive 
symptoms in adults. 
  *State Trait Anxiety 
Inventory (STAI) 
20 items to measure anxiety 
symptoms and how the client feels in 
general. 
  *Clinical Diagnostic 
Questionnaire 
(CDQ) 
A substance abuse and mental health 
screening instrument that can be 
administered by lay interviewers. 
 * Denotes scales used to assess caregivers. 
 
 3.3.3 Antiretroviral Treatment (ART) Regimens 
Some studies detailed the drug regimens administered (which consisted of 
combinations of NRTI‘s, NNRTI‘s and PI‘s) but did not include the CNS penetration 
ratings.  Prospective studies documented neurodevelopment pre and post HAART, 
from baseline to treatment periods ranging from 6 months to 3 years.  Retrospective 
studies conducted chart reviews that documented changes in CNS and 
neurocognitive functioning during several years of HAART treatment.  
 
3.4 KEY FINDINGS FROM THE LITERATURE REVIEW 
 3.4.1 Impact of HAART across the spectrum of HAND 
Studies specifically exploring the impact of HAART on PHE all demonstrated 
dramatic declines in incidence, that PHE is a reversible complication of HIV, with 
high degrees of neurological improvement, after initiation of HAART (Sanchez-












ART before the onset of PHE is neuroprotective and appears to alter the natural 
history of neurological outcome, in the majority of cases (Toledo-Tamula MAT et al 
2003, Sanchez Ramon S et al 2003, Hazra R et al 2007).  However, there is a risk 
of relapse if viral control is lost.  The highest risk of relapse is in the group of 
children with arrested encephalopathy.  Improvements in children who were 
previously diagnosed with PHE are less impressive after ART.  There are higher 
rates of residual neurocognitive, neurological and scholastic difficulties compared to 
those with no prior diagnosis of PHE (Chiriboga CA et al 2005).  Neurocognitive 
testing indicates that scores generally improve (compared to neurocognitive 
performance of untreated children), with IQ scores clustering in the average range 
compared to low average to borderline range in untreated children (Martin SC et al 
2006).  However, scores remain lower than population norms, with a trend for 
scores to be poorer than Perinatally HIV Exposed Uninfected (PHEU) children and 
HIV negative children (HNU).  In children with arrested PHE, IQ scores either 
remain static or do not increase significantly, remaining well below the standard 
mean of 100 (Chiriboga CA et al 2005).  A few studies, however, indicate that 
despite virological stability, some children can experience significant declines in 
neurocognitive functioning that is not explained by environmental risk factors.  This 
appears to reverse when HAART regimens are changed to CNS penetrating drugs 
(Toledo-Tamula MAT et al 2003, Shanbag MC et al 2005).  Most studies 
demonstrated persistent and significant neuropsychological deficits, particularly in 
language, verbal fluency, working memory, attention deficits, processing speed, and 
visuospatial tasks. 
3.4.2 Neurocognitive performance in older school going children and adolescents 
receiving HAART 
Studies specifically exploring the neurocognitive and school functioning of older 
children and adolescents demonstrate that school aged HIV positive children have 
lower neurocognitive functioning than aged matched PHEU and HNU children 
(Puthanakit T et al 2010).  However, compared to age matched ART unexposed 
children, IQ scores are higher, clustering within the normal range.  Despite this 
improvement in overall neurocognitive functioning, this group still perform more 
poorly academically compared to HIV negative controls and PHUE children.  
Significant percentages of children continue to require specialized educational input 
or referral to special schools (Brackis-Cott E et al 2009, Souza E et al 2010).  












these children.  This may explain their relatively poorer academic performance 
despite their composite IQ scores falling within the average range (Koekoek S et al 
2008).  The findings of a study by Brackis-Cott demonstrated that older HIV infected 
and affected children and adolescents present with poor language skills (poor verbal 
skills, limited vocabulary and basic reading skills).  The findings highlight the 
importance of educational interventions to address this problem that, if not 
remediated, may affect the overall health literacy (and adherence) in infected youth 
as they age and assume greater treatment responsibility (Brackis-Cott E et al 2009). 
3.4.3 Specific medical and CNS variables associated with global and/or specific 
neurocognitive functioning 
Most studies demonstrated consistent increases in CD4 counts and significant 
decreases in viral loads after ART.  However, studies exploring the neurocognitive 
impact of long-term ART do not demonstrate significant improvements in 
neurocognitive functioning, despite virological control and improvements in neuro-
immune indices.  The findings suggest that early neurotoxicity occurring during the 
first years of life may be irreversible and that early initiation of ART in infants and 
young children should be a consideration in order to preserve neurocognitive 
functioning (Puthanakit T et al 2010).  Studies linking neurocognitive outcomes with 
immune indices and viral loads differed with regard to outcomes.  A study by 
Lindsey demonstrated that more severe immune suppression was associated with a 
greater risk of problems in neurodevelopment.  However, the study by van Loon 
demonstrated that HIV positive children show poorer neurocognitive performance 
than HIV negative children do, regardless of their stage of disease, immune status, 
or type of ART (Lindsey JC et al 2007, Van Loon S et al 2009).  Similarly, some 
studies suggested poorer neurocognitive outcomes (development of PHE) in 
children with higher baseline viral loads (Chiriboga CA et al 2005, Jeremy RJ et al 
2005) and others not (Martin SC et al 2006).  There was, however, a significant 
relationship between Processing Speed and CD4 measures, in effect; children with 
CD4 counts of below 500 had significantly poorer processing speed than children 
with CD4 counts of above 500.  Children with CD4 counts of above 500 performed 
significantly better on tests such as Digits Backwards, Coding, Symbol Search, and 
Picture Arrangement (Martin SC et al 2006). 
However, other studies linking neurocognitive functioning with disease stage 












greater risk of neurocognitive and neurological deficits and that these deficits 
persisted despite initiation of HAART.  This suggests that early initiation of HAART 
(before onset of neurocognitive deficits or during infancy) is necessary in order to 
preserve the developing CNS.  Other studies also indicated that the greatest 
neurocognitive gains were achieved in younger children started on treatment early 
in the disease process and poorer gains in older children, again demonstrating 
irreversibility of early pervasive damage (Smith L et al 2010, Sanchez-Ramon S et 
al 2003).  
 3.4.4 Impact on Cerebrospinal Fluid (CSF) viral load 
 
Shanbag et al demonstrated a significant decline in the prevalence of PHE and 
improvement in overall neurocognitive status in a sample of 146 perinatally infected 
children initiated on HAART.  However, a significant number of children continued to 
present with neurocognitive delay, suggesting discordant patterns of viral resistance 
between plasma and CSF (Shanbag MC et al 2005).  Similarly, a prospective study 
conducted by Mc Coig et al measured CSF viral loads in plasma and CSF, and 
revealed discordant patterns of viral evolution, with mutations emerging associated 
with resistance to certain ART regimens particularly 3TC (Mc Coig C et al 2002).  
Other studies demonstrated neurocognitive declines despite significant reduction in 
viral loads suggesting poor CSF penetrance of certain antiretroviral agents.  This 
neurocognitive decline was reversed or arrested when patients were changed to 
CSF penetrating regimens (Toledo-Tamula MAT et al 2003, Shanbag MC et al 
2005).  
 
 3.4.5 Neurological status  
 
Those studies that included neurological examination and neuroimaging 
assessments consistently demonstrated that neurocognitive and neuropsychological 
performance of children with neurological deficits and brain scan abnormalities is 
significantly poorer than those without (Foster C et al 2006, Thomaidis Let al 2010).  
Some studies demonstrate that neuroimaging abnormalities persist after 6-12 
months on HAART, with ventricular enlargement and subarachnoid dilatation 
commoner than white matter abnormalities and calcifications (Martin SC et al 2006, 
Smith L et al 2008, Thomaidis L et al 2010).  Others report minimal CT brain 
abnormalities after 96 weeks of HAART, suggesting a neuroprotective effect of 












infected children on HAART were performing in the normal range for composite 
neurocognitive scores and specific indexes, subsets of children with neurological 
deficits performed more poorly on neuropsychological tests.  This was particularly 
so on those testing working memory, logical sequencing and planning, visual spatial 
organization and attention to visual details (Martin SC et al 2006). 
 
 3.4.6 ‘Non HAART’ variables 
 
Higher caregiver-child ratios and positive home environments which included 
parental involvement and the provision of stimulation were associated with higher 
full scale IQ‘s, indicating the need to focus on early intervention in socio-
economically deprived infected children (Shanbag MC et al 2005).  The study by 
Lindsey et al demonstrated differences in neurocognitive scores between PHIV and 
PHUE children, with poorer functioning in the infected group.  The differences 
between the two groups, however, diminished over time, suggesting that other 
(probably psychosocial) factors had affected neurocognitive functioning (Lindsey JC 
et al 2007).  
 
 3.4.7 Psychopathology 
High rates of psychiatric disorders and psychiatric hospitalization were found in HIV 
infected children.  Prevalence rates ranged between 25% and 52% in some studies.  
This rate exceeded population norms and rates in other chronically ill children, but 
was similar to that of clinical samples of psychiatrically referred youth (Gaughan DM 
et al 2004, Mellins CA et al 2006, Nozyce M et al 2006, Wood SM et al 2009).  Later 
studies demonstrated equal rates of psychopathology in PHIV and PHEU older 
children and adolescents (Chernoff M et al 2009, Mellins CA et al 2009, Gadow K et 
al 2010, Mallee K et al 2011), indicating a risk of psychopathology regardless of 
infection in HIV exposed youth.  This was thought to be due to the in utero exposure 
to HIV, similar psychosocial stressors.  The authors suggest that the lack of 
differences in rates of psychopathology could be related to increased access to 
services by HIV positive youth, who may receive more comprehensive interventions 
for behavioural and emotional problems (than PHEU youth).  Two studies reported 
low rates of depression and DSM IV disorders respectively (Lee B et al 2011, New 
MJ et al 2006), indicating possible resilience in HIV positive youth, but also 
underreporting on the part of caregivers.  The study by New also reported high 












authors impacted on the utility of the screening instrument used (C-DISC 4), a 
computerized scale (New MJ et al 2006). 
The commonest psychiatric presentations were mood disorders, disruptive 
behaviour disorders (particularly ADHD), anxiety disorders, and substance use 
disorders (SUDs) (Misdrahi D et al 2004, Mellins CA, Elkington KS et al 2009, 
Mellins CA. Brackis-Cott et al 2009, Wiener L et al 2006).  There was a lack of 
gender differences in samples presenting with ADHD, suggesting a direct impact of 
HIV on the brain (Nozyce M et al 2006).  Later studies focused on psychopathology 
in adolescents and revealed high rates of depression, non-disclosure (of HIV status 
in school settings), school dropout, sexual risk behaviour, and SUDs (Mellins CA, 
Elkington KS et al 2009, Souza E et al 2010).  A study by Wiener revealed high 
rates (45%) of psychotropic drug use compared to the normative population, but 
similar to psychiatric populations.  The most prescribed medications were 
antidepressants (30%, Sertraline most commonly used), followed by stimulants 
(25%), then atypical antipsychotics (16%).  Higher rates of psychotropic medication 
use was found in children who had lost a parent to HIV, suggesting that mourning 
may be complicated by factors such as secrecy, stigma, and previous losses.  The 
study also demonstrated high rates of depression in the older sample of youth, 
which was particularly associated with parental loss but which may also have been 
related to other psychosocial stressors, genetic or immune factors (Wiener L et al 
2006).  Similarly, a study by Chernoff revealed high lifetime rates of psychotropic 
drug use in HIV positive youth, despite equal rates of symptomatology and 
impairment between HIV positive and HIV negative (HIV exposed) youth (Chernoff 
M et al 2009). 
Studies which explored the aetiology and risk factors associated with 
psychopathology did not consistently reveal specific links with HIV, neuroimaging 
abnormalities, or other disease related factors, concluding that the aetiology was 
likely to be a multifactorial combination of biological and environmental factors.  
However, a study by Woods et al examined the relationship between severity of HIV 
disease and psychiatric and neurocognitive outcomes.  Results demonstrated a 
significant association between lifetime history of psychiatric illness and severe HIV 
disease (category C diagnosis) (Woods SM et al 2009).  Another study revealed that 
lower child IQ, younger age, caregiver psychiatric disorder, and limit setting 
problems from caregiver to child were associated with higher odds of presenting 












demonstrated an indirect effect of caregiver psychiatric symptoms on youth 
psychiatric symptoms and substance use (Mellins CA, Elkington KS et al 2009).  
Later studies revealed PHEU youth to be at equal or greater risk of 
psychopathology.  This may be due to shared factors such as in utero exposure to 
HIV and shared genetic and environmental stressors (Chernoff M et al 2009, Mellins 
CA, Elkington KS et al 2009, Mellins CA, Brackis-Cott et al 2009).  Equal or lower 
rates of psychopathology in HIV positive youth may also be due to greater access to 
comprehensive interventions for emotional and behavioural problems by HIV 
positive youth.  Service related issues that were highlighted were those related to 
the link between caregiver mental health and youth outcomes, recommending 
integrated mental health services for caregivers and children, and greater access to 
services for HIV affected (uninfected) youth.  Effective strategies for reducing HIV 
transmission and reducing risk behaviour would be to incorporate interventions into 
existing mental health programmes (Mellins CA, Elkington KS et al 2009). 
 
3.5 STRENGTHS AND WEAKNESSES OF THE STUDIES REVIEWED 
 
The studies generally were of a high quality but with relatively few prospective 
studies (9).  Sample sizes varied widely, ranging from infancy through to 
adolescence.  Comparison groups consisted of HIV exposed but uninfected children 
or HIV unexposed HIV negative children from similar ethnic and socio-economic 
backgrounds.  This however may still lack generalizability as most studies were 
conducted in the developed world.  Well validated neurocognitive tests, 
neuropsychological batteries, and instruments to test psychopathology were used.  
Later studies considered multiple variables that may impact on neurobehavioural 
presentations.  However, the relatively small sample sizes in some studies could 
have influenced their statistical power to identify the specific biological and 
environmental factors that impact on the neurocognitive and mental health 
outcomes in PHIV children and adolescents.  Few of the prospective studies 
particularly explored neurobehavioural functioning pre and post HAART.  No studies 
explored the potential neurotoxic side effects associated with HAART.  None of the 
studies explored the nature of the ADHD diagnosis in HIV positive children and how 
this may differ compared to HIV negative children in terms of diagnostic criteria, 












This is of potential significance considering that early studies suggest that 
aetiologically, an ADHD diagnosis may indicate a direct effect of the virus (derived 
from the lack of the usual ADHD gender differences in HIV positive children).  This, 
coupled with the high prevalence of neuropsychological deficits revealed on testing, 
may indicate that an ADHD diagnosis is associated with significant 
neuropsychological deficits, showing early HIV encephalopathy in otherwise 
asymptomatic PHIV children.  The lack of prospective study design and the small 
number of studies exploring HAART impact, particularly adverse neurocognitive and 
behavioural effects of Efavirenz, represents a gap in the current literature, which 
should be further explored. 
 
3.6 CONCLUSION 
A review of the literature exploring the neurobehavioural profile of PHIV children in 
the post HAART era reveals that despite higher rates of survival and substantially 
lower rates of PHE, a small percentage may still present with neurocognitive decline 
and neurological impairments, particularly those with known CNS disease and more 
severe immunosuppression.  However, most children on neuropsychological testing 
demonstrate improved composite IQ scores, but continue to present with milder 
neurocognitive deficits, particularly language and memory deficits, and problems 
with processing speed.  Such deficits negatively impact on academic performance 
and may impact on health literacy (and adherence) as they assume increased 
responsibility for th ir treatment during adolescence and early adulthood.  
Furthermore, PHIV children continue to perform more poorly than PHEU and HNU 
children do, despite shared perinatal and psychosocial stressors in the PHEU group.  
This may indicate a possible viral aetiology for neurocognitive problems.  Studies 
reveal that the greatest neurocognitive gains are achieved in younger children 
initiated on HAART early in the disease process, suggesting that slower gains in 
older children demonstrate irreversibility of pervasive early damage.  Furthermore, 
greater neurocognitive improvements may be achieved in children on HAART 
regimens with high CNS penetration.  Recommendations include serial 
neurocognitive (neuropsychological) testing and neuroimaging in children on 
HAART, early initiation of HAART ideally during infancy or early in the disease 












Studies that explored the nature and rates of psychopathology in PHIV youth, 
demonstrate high school dropout rates and non-disclosure of HIV status among 
PHIV adolescents.  A number of studies demonstrated high rates of behavioural 
problems, psychiatric diagnoses, and risk taking behaviours in both PHIV and PHEU 
youth.  Commonest psychiatric diagnoses are mood disorders (particularly during 
adolescence), ADHD (higher in PHIV youth) and anxiety disorders.  Causes are 
likely multifactorial with no direct link with disease severity found.  Caregiver mental 
health may influence youth risk behaviour highlighting the importance of 
interventions for caregivers and the need for integrated mental health services (for 
children and adults).  Some studies identified PHEU youth as a high risk group, with 
higher rates of psychopathology, a reflection of increased access to more 
comprehensive services for PHIV youth.  Recommendations include comprehensive 
and integrated mental health services at HIV clinics, for caregivers, PHIV, and 
PHEU youth.  Early detection of academic problems should be a focus at such 
clinics.  Incorporation of HIV prevention programmes and interventions to reduce 
risk behaviours may be an effective method of reducing HIV transmission by 
sexually active PHIV youth.  
The following and final chapter consists of the discussion and concluding remarks.  
It will provide a brief summary and aetiological formulation of the clinical review of 
the patients evaluated at the neuropsychiatric clinic.  This will be related and 
compared to the findings of the comprehensive literature review (chapter 3) in order 
to make clinical and educational recommendations as well as suggestions for future 
clinical research. 














This chapter, the discussion and concluding remarks, comprises an elaboration and 
aetiological formulation of the clinical case series with reference to the findings of 
the systematic literature review.  Clinical, educational and research 
recommendations will be discussed. 
 
4.1 DISCUSSION 
The clinical cohort reviewed is a group of institutionalized South African PHIV 
children who were born prior to the national rollout and who were initiated on ART 
years after HIV diagnosis.  Therefore, it could be anticipated that such a group was 
likely to present with HAND, despite immune reconstitution.  In all of them, treatment 
was initiated relatively late and after the disease had progressed clinically.  The nine 
children indeed presented with significant learning and behavioural problems 
necessitating transfer to special schools, as well as referrals for psychiatric 
evaluation.  Explanations for the neurocognitive and psychiatric presentations are 
likely to be a combination of biological and psychosocial factors that may have 
impacted on these children. 
 
Aetiological factors for the poor academic performance of the clinical cohort were 
biological factors such as pre- or perinatal insults to the brain, the direct CNS effect 
of HIV, neurological complications and the impact of co-morbid illnesses associated 
with HIV.  Unfortunately, detailed histories of the pre and perinatal period were not 
available.  However, one child was formally diagnosed with FAS and another 
presented with microcephaly and facial features of FAS, which is known to be 
associated with neurocognitive and behavioural deficits (Riley EP et al 2005).  An 
additional two children may have been prenatally exposed to alcohol, as there were 
confirmed histories of longstanding alcohol abuse by the mothers.  It was, however, 
not possible to identify a direct effect of HIV on the brain in the absence of a control 
group and in such a small sample.  Furthermore, it was not possible to establish 
whether neurocognitive performance of this HIV infected group of children was 
poorer than an age matched group of HIV negative (PHEU or unexposed children) 
as suggested in the literature.  However, test scores were similar to that reported in 












disability.  A direct correlation between IQ scores and degree of 
immunocompromise was not established in the cohort, most likely due to the small 
sample size.  It was, therefore, not possible to verify the findings of the literature 
review which suggest an association between poor neurocognitive performance, 
degree of immune compromise and higher baseline viral loads. 
 
The literature review revealed that neurological impairments are associated with 
poorer neurocognitive outcomes and an overall poorer prognosis.  In the case of the 
clinical cohort reviewed, most of the children did not present with significant HIV-
related CNS deficits.  The exceptions were EEG examinations, which were 
abnormal in two of the children, both of whom tested within the lowest IQ range for 
the group (composite IQ‘s less than 60).  The abnormal EEG, therefore, may have 
been a sign of early encephalopathy in the absence of neurological impairment, as 
suggested in studies exploring the association between EEG, onset of 
encephalopathy and disease progression (Roy S et al 1992, Udgirkar VS et al 2003, 
Vigliano P et al 1997). 
 
Environmental factors associated with a negative impact on the children‘s 
neurocognitive and academic perf rmance may be those related to institutional 
care, multiple caregivers and poor quality of caregiver/child interaction.  Greater 
levels of behaviour problems, growth, neurocognitive, and language development 
deficits have been demonstrated in institution reared children for more than fifty 
years (MacLean K et al 2003, Rutter M et al 2007).  Studies that are more recent 
confirm serious impairments in social behaviour (Zeanah CH et al 2005) with 
disturbances in cortisol regulation, presumed to be due to high levels of stress 
(Carlson M et al 1997).  A study by Smyke et al demonstrated that children were not 
equally affected by institutional care and that predictors of children‘s‘ development 
were related to length of institutional care, but mostly to the quality of caregiving 
(Smyke AT et al 2007).  Dobrova Krol 2010 et al explored the effects of perinatal 
HIV infection and compared the stress regulation, neurocognitive, and physical 
growth of family reared and institution reared HIV positive children.  They 
demonstrated that physical and neurocognitive development of family reared HIV 
positive children, even of a compromised quality, was more favourable than 
institution reared children, despite adequate provision of healthcare and nutrition.  












institutional environment might have been a source of daily intermittent stress 
(Dobrova-Krol NA et al 2010). 
 
The clinical sample was resident at a children‘s home, which unfortunately 
experienced a high turnover of staff.  Some of the children were also exposed to 
inconsistent parenting by multiple caregivers and ‗fraught‘ caregiver-child 
relationships during their early years (later on the children were placed in cottages 
with two consistent carers), which may have contributed to a poorer quality of 
caregiving environment. 
 
School related environmental factors that may have negatively affected the 
children‘s academic performance are those related to high rates of absenteeism 
(frequent hospitalizations and clinic visits) and placement at mainstream schools, 
where they coped poorly with the academic demands and pace of work.  These 
schools were unlikely to have provided the specialized educational support that 
these children required.  Large classes, in excess of thirty five children per grade, 
would also have reduced opportunities for regular ‗one on one‘ contact with the 
class teacher.  Those of the children who attended special schools did benefit from 
smaller classes, regular teacher contact, and a more appropriate curriculum suited 
to their intellectual ability. 
 
Aetiological factors that contributed to the psychiatric presentations of the children 
assessed were biological factors such as genetic predispositions to mental illness, 
pre- or perinatal factors, HIV factors, possible adverse effects of ART, psychological 
and psychosocial factors.  It was not possible to identify family histories of major 
mental illness as the information was not available in the case records and contact 
with family members was either absent or minimal.  However, two of the mothers 
were known to abuse alcohol and experienced emotional difficulties.  Prenatal 
exposure to alcohol was known in the case of two children, one of whom was 
formally diagnosed with FAS.  This may have predisposed them to ADHD that is 
highly prevalent among children with FAS.  No specific virally-related causes for the 
behavioural presentations of the clinical cohort could be established.  It does 
however; provide detailed insights into the lived experiences of children living with 
HIV in South Africa and highlights the complex interwoven factors that have 












provide an opportunity for hypothesis development, for future research studies with 
larger samples and comparison groups. 
 
The comprehensive literature review similarly failed to definitively establish a HIV-
related cause for psychiatric presentations and suggest that the aetiology of 
psychiatric presentations is a combination of biological and psychosocial factors.  
While it was not possible to identify a direct link between the psychiatric 
presentations and the antiretroviral medications prescribed, possible neurotoxic side 
effects were considered, as eight of the nine children were on a regime containing 
the NRTI AZT, which is associated with neuropsychiatric complications such as 
mania, depression, agitation, confusion and insomnia.  One of the children 
presented with confusion, inattention, and perceptual disturbances.  She was on a 
medication regime containing Efavirenz, which is associated with perceptual 
disturbances, agitation, confusion, stupor, amnesia, and impaired concentration.  No 
studies, however, were identified in the literature review that specifically explored 
adverse behavioural and neurocognitive side effects of ART in children. 
 
Psychological factors considered were attachment disturbances and the 
psychological impact of chronic illness: this group of children were mostly 
abandoned during infancy and placed in a children‘s home.  They were, therefore, 
unlikely to have experienced secure attachments to a primary caregiver.  This was 
demonstrated in the quality of attachment to the caregivers from the children‘s 
home, which was ambivalent and in most instances showed patterns of ‘insecure‘ or 
‗disorganized‘ attachment.  The attachment disturbances appeared to be pervasive 
and the source of the interpersonal difficulties between the children, their peers, and 
their caregivers at the children‘s home.  The psychological impact of chronic illness 
was related to frequent episodes of illness, hospitalization and exposure to the 
death of their peers and fears of their own death, all of which was likely to be highly 
anxiety provoking and linked to their prior abandonment experiences. 
 
Psychosocial factors that contributed to the psychiatric presentations of the children 
were those related to the school environment, institutionalization, and the impact of 
placement plans and reunification with family.  This sample of institutionalized HIV 
positive children were largely shielded from the known psychosocial stressors 












parental illness, parental mental illness, substance abuse, and parental loss.  
However, a different set of factors impacted significantly on their psychological 
wellbeing, such as poor coping in mainstream schools and having to negotiate the 
transition to adolescence (with the added complication that they would be faced with 
leaving the children‘s home).  A number of stressors appeared to be more specific 
and unique to this sample.  These included being in institutionalized care, factors 
related to the particular children‘s home they were resident at, issues related to the 
socio-economic disparity between the children and their biological families, cultural, 
and language differences.  The impact of the national ‗roll out‘ could also be viewed 
as a stressor as the children‘s improved health led to an increased impetus to 
reunite the children with their families of origin, an experience which was not always 
experienced positively during the initial period of contact between the children and 
their families. 
 
4.2 CLINICAL, EDUCATIONAL AND RESEARCH 
RECOMMENDATIONS. 
 
By reviewing the findings of the case series and relating them to the systematic 
literature review, the following clinical educational and research recommendations 
are proposed. 
 
 4.2.1 Clinical recommendations 
 
Baseline evaluation of the HIV positive child at diagnosis should ideally consist of 
medical, neurological, and developmental assessments, as well as a mental health 
screen.  This type of comprehensive assessment is likely to be limited by service 
constraints in a resource-limited setting such as South Africa, where routine 
developmental and neurocognitive assessments would not be feasible for all HIV 
positive children.  Scaled up delivery of ART to PHIV South African children has 
progressed significantly during the past few years and increasing numbers of 
studies have reported favourable outcomes (Bock P et al 2008, Eley BS et al 2011).  














A realistic aim for a comprehensive assessment would be to adopt a 
biopsychosocial approach at primary level in order to address multiple risk factors 
for poor neurocognitive outcomes.  Richter et al propose integrated and family 
based models of care whereby mothers and children are managed within the same 
setting, in order to strengthen ‗Prevention of Mother-to-Child Transmission Therapy‘ 
(PMTCT), early diagnosis and ART initiation (Richter L et al 2009).  Within this 
integrated system, one could then also implement psychosocial interventions such 
as parenting education and support, as well as early childhood intervention services.  
The creation of useful, but simple, screening instruments are essential.  These could 
then be used by a clinician, in a primary care setting, as a valuable and cost 
effective method of early identification of problems.  The aim of the initial screening 
would be to identify early neurological and neurocognitive deficits as well as 
behavioural problems, which form the clinical triad of PHE.  Such brief screening 
instruments do not to my knowledge exist, but would take the form of brief 
‗checklists‘ screening for motor problems, neurocognitive, and behavioural changes. 
 
The second ‗tier‘ of assessment should be offered by multidisciplinary teams 
consisting of Paediatric Neurologists, Developmental Paediatricians, Child 
Psychiatrists, Clinical, or Neuropsychologists at secondary levels of care.  The aim 
of the multidisciplinary assessments and follow-up would be to identify, monitor, and 
evaluate CNS symptoms, neurocognitive deficits, and psychiatric presentations, 
including ADHD.  Multidisciplinary clinics would strengthen and promote integrated 
models of family bas d care, which ideally should provide medical and mental 
health services for caregivers as well as the children within the same clinic at all 
levels of HIV care.  Children identified as ‗at risk‘ of encephalopathy, or who present 
with psychopathology, may then be referred to specialist services at tertiary level. 
 
Early initiation of HAART for mother and child is an important aspect of the 
management of the HIV positive child, in order to achieve favourable outcomes and 
to prevent and treat HAND.  Recent studies demonstrate clear indirect benefits to 
the child when their parents are treated, such as decreases in diarrhoea, 
hospitalisations, and mortality, as well as improvements in school enrolment and 
nutritional status.  These studies also show that family members significantly impact 
on adherence, mental health, and treatment outcomes of other family members 












integrated care for the child in the context of the family, in order to achieve improved 
outcomes.  Antiretroviral agents with known CNS penetration should be the 
treatment of choice in children presenting with neurocognitive deficits or 
neurological and psychiatric symptoms.  Detection and monitoring of adverse CNS 
effects of ART should be undertaken by clinicians involved in the care of the child 
and reported to the infectious diseases clinician responsible for HIV treatment.  
 
Early screening and intervention strategies should go hand in hand with services to 
enhance children‘s‘ development and prevention of mental health problems.  The 
former may be strengthened via state-supported preschool programmes, free 
education and health care, school feeding and removing barriers to ART.  
Prevention and intervention strategies for mental health problems in children and 
adolescents could be achieved via provision of strengthened child protection 
services, provision of social skills, HIV awareness, and sex education groups for 
HIV positive adolescents.  Parenting interventions, psycho-education and mental 
health intervention for caregivers, home visits, and provision of increased numbers 
of mental health practitioners at all levels of care would add support. 
 
 4.2.2 Educational recommendations 
 
Early detection and intervention of educational difficulties are often logistically 
problematic, as in many instances, educators and school psychologists are not 
aware of the child‘s HIV status.  However, in cases where a child‘s status is known 
and consent by the caregiver granted, the creation of a database of children infected 
with HIV at various schools should be considered.  This confidential record could be 
centralized and managed by school psychology services in the province.  In that 
way, children‘s‘ academic progress, school attendance, behavioural profiles and 
school transfers could be monitored on a regular basis.  A coherent plan of 
intervention, referral, and liaison with healthcare providers may then be formulated.  
At school level, referral of a child identified as at ‗risk‘ by the educator could feasibly 
be to the educational psychologist assigned to the school.  This would be in order to 
evaluate and monitor academic progress and to refer to specialist medical services, 
should there be a suspicion of neurocognitive decline.  The educational psychologist 
along with the teacher may then formulate a specific educational plan.  They could 












school, if deemed necessary.  While it is acknowledged that additional remedial 
support to address the educational needs of HIV infected children will be necessary 
if there is to be any hope of success, funding constraints would significantly impact 
on the Education Department‘s capacity to provide the additional human resources 
to intensify remediation or conduct regular routine psychometric testing of all HIV 
positive learners.  For this reason, it is recommended that a task team be created in 
order to compile a framework within which submissions could be made to the 
national department to consider specialized funding streams for remedial 
interventions for children infected with HIV. 
 
 4.2.3 Research Recommendations  
 
The literature review reveals a paucity of studies exploring the psychiatric sequelae 
of HIV in children.  A number of remaining questions about the neurocognitive and 
psychiatric outcomes need to be answered.  This could be done via further long-
term prospective studies, which would be a useful way to track the long-term 
outcome of HIV positive children previously diagnosed with psychiatric disorders 
during childhood and followed up to adolescence and early adulthood.  Studies 
exploring treatment effects (treatment response, drug interactions), including the 
psychiatric side effects of ART as well as the impact of long-term ART on the course 
and outcome of psychiatric presentations, should be further explored.  A local study 
which would compare a group of psychiatrically referred HIV positive children, to a 
group of infected, psychiatrically asymptomatic children, will be useful to identify the 
unique risk factors for psychopathology in HIV positive children and adolescents in 
South Africa.  Another local study examining school attendance, placement at 
special schools and the presence of academic problems in a sample of PHIV 
children, will be extremely useful in clarifying the educational needs of infected 




HIV in the HAART era continues to impact significantly on children‘s long-term 
survival, neurodevelopment, and mental health.  Despite the longstanding record of 












remains unacceptably low for HIV infected children compared to adults (Leeper SC 
et al 2010).  This is of particular concern in Sub Saharan Africa, where substantial 
numbers of children remain at risk of being infected with HIV, as average 
‗Prevention of Mother to Child Transmission Therapy‘ (PMTCT) coverage remains 
only 58% (Richter LM et al 2009).  Studies conducted in South Africa are few and 
correspond with the literature, confirming poorer neurocognitive performance in 
PHIV compared to PHEU and HNU children.  High rates of neurocognitive deficits, 
particularly language deficits are evident, despite having been initiated on HAART.  
The authors suggest that this finding may be a reflection of the relatively late 
initiation of ART in South African children and recommend early HAART, during 
infancy, before the onset of neurocognitive deficits (Smith L et al 2008). 
 
My impression (based on years of assessing children referred for psychiatric 
evaluation) is that significant numbers of South African children continue to present 
late at diagnosis and as a result, they are late for treatment initiation and therefore 
remain at risk of the irreversible neurocognitive and CNS sequelae of HIV.  Adverse 
social circumstances are in many instances a barrier to care and delay ART 
initiation, as reliable adults need to be identified and counselled to assume 
responsibility for follow up visits and administration of medication at home.  Other 
difficulties are that among some children living at home, adherence and clinic visits 
are erratic.  Mothers themselves experience poor physical and mental health, and 
some abuse substances, all of which negatively impact on the care of the child.  
Children then have to rely on multiple surrogate caregivers (often grandmothers) 
within extended families to monitor treatment.  The unfortunate consequence is that 
some of them develop treatment failure due to viral resistance.  Significant numbers 
of such children merit referral to social services for investigation and monitoring of 
their home circumstances, but my impression is that referrals are either relatively 
few or that those referred experience limited services or intervention by statutory 
agencies.  The majority of such children remain enrolled at school but present with 
significant learning problems when presenting for psychiatric evaluation.  Many of 
them are not receiving specific remedial interventions. 
 
Holistic interventions which aim at early initiation of ART, prevention, detection of 
and early intervention of neuropsychiatric problems will improve long-term outcomes 
of HIV infected children as they survive into adulthood.  Comprehensive and 












and developing world settings and produces good outcomes in terms of adherence 
and retention, service uptake and clinical prognoses (Leeper SC et al 2010).  These 
need to be taken into consideration by those involved with healthcare policy and 
planning so that infrastructural capacity and healthcare personnel may be 
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